

=> d que

L1 16 SEA FILE=REGISTRY ABB=ON PLU=ON RRRPRPPYLPRPRPP/SQSP
 L2 2 SEA FILE=REGISTRY ABB=ON PLU=ON ("PR 39"/CN OR "PR 39 (ION
 EXCHANGER)"/CN OR "PR 39 (PEPTIDE)"/CN)
 L4 53 SEA FILE=HCAPLUS ABB=ON PLU=ON L1 AND (L2 OR PR39 OR PR 39)
 L5 8645 SEA FILE=HCAPLUS ABB=ON PLU=ON ANGIOGENESIS+NT/CT
 L6 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L1 AND (L5 OR ANGIOGEN?)
 L7 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L4 AND (L5 OR ANGIOGEN?)
 L8 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L6 OR L7

=> d ibib abs hitstr 18 1-6

L8 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:220416 HCAPLUS
 DOCUMENT NUMBER: 136:257252
 TITLE: Method of modulating neovascularization
 INVENTOR(S): Kovesdi, Imre
 PATENT ASSIGNEE(S): Genvec, Inc., USA
 SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022176	A1	20020321	WO 2001-US28954	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001091019	A5	20020326	AU 2001-91019	20010914
PRIORITY APPLN. INFO.:			US 2000-233001P	P 200000915
			WO 2001-US28954	W 20010914

AB The present invention provides a method of modulating neovascularization in an animal. The method comprises administering to the animal two or more nucleic acid sequences, each nucleic acid sequence encoding at least one angiogenesis-modulation factor that acts upon a different angiogenic process, such that the nucleic acid sequences are expressed to produce the angiogenesis-modulation factors to modulate neovascularization in the animal. Modulating neovascularization includes the induction of neovascularization or, in the alternative, the inhibition or redn. of neovascularization.

IT 139637-11-9, PR39 peptide
 RL: BUU (Biological use, unclassified); PAC (Pharmacological activity);
 BIOL (Biological study); USES (Uses)
 (method of modulating neovascularization)
 RN 139637-11-9 HCAPLUS
 CN L-Prolinamide, L-arginyl-L-arginyL-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-

THIS PAGE BLANK

prolyl-L-tyrosyl-L-leucyl-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-
 prolyl-L-prolyl-L-phenylalanyl-L-phenylalanyl-L-prolyl-L-arginyl-L-
 L-leucyl-L-prolyl-L-prolyl-L-arginyl-L-isoleucyl-L-prolyl-L-prolylglycyl-L-
 phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-phenylalanyl-L-prolyl-L-prolyl-
 L-arginyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 6 HCPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:319740 HCPLUS
 DOCUMENT NUMBER: 134:336214
 TITLE: Method for PR-39 peptide regulated stimulation of angiogenesis
 INVENTOR(S): Simons, Michael; Gao, Youhe
 PATENT ASSIGNEE(S): Beth Israel Deaconess Medical Center, USA
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030368	A1	20010503	WO 2000-US27552	20001006
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.: US 1999-426011 A 19991025
 AB The present invention provides both a method and means for regulating angiogenesis within living cells, tissues, and organs in-situ. The regulation is performed using native PR-39 peptide or one of its shorter-length homolog, for interaction with such proteasomes as one present in the cytoplasm of viable cells. The result of PR-39 peptide interaction with proteasomes is a decrease in the intracellular degrdn. of active peptides such as HIF-1.alpha. and a consequential stimulation of angiogenesis in-situ.


IT 298702-64-4
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (PR-39 peptide regulated stimulation of angiogenesis)

RN 298702-64-4 HCPLUS
 CN L-Proline, L-arginyl-L-arginyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-
 prolyl-L-tyrosyl-L-leucyl-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.

THIS PAGE BLANK (USPTO)

PAGE 1-A



PAGE 1-B



THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

or one of its shorter-length homologs, for interaction with such proteasomes as one present in the cytoplasm of viable cells. The result of **PR-39** peptide interaction with proteasomes is a decrease in the intracellular degrdn. of active peptides such as HIF-1. α . and a consequential stimulation of **angiogenesis** *in-situ*.

IT 298702-64-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(PR-39 peptide-regulated stimulation of angiogenesis)

RN 298702-64-4 HCAPLUS

CN L-Proline, L-arginyl-L-arginyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-
prolyl-L-tyrosyl-L-leucyl-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




THIS PAGE BLANK (USPTO)

PAGE 1-B



PAGE 2-B



IT 148046-54-2

RL: PRP (Properties)

(unclaimed protein sequence; method for PR-39
peptide regulated stimulation of angiogenesis)

RN 148046-54-2 HCAPLUS

CN L-Proline, L-arginyl-L-arginyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-
prolyl-L-tyrosyl-L-leucyl-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-
prolyl-L-prolyl-L-phenylalanyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-
L-leucyl-L-prolyl-L-arginyl-L-isoleucyl-L-prolyl-L-prolylglycyl-L-
phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-phenylalanyl-L-prolyl-L-prolyl-
L-arginyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMATL8 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:178321 HCAPLUS

THIS PAGE BLANK (USPTO)

DOCUMENT NUMBER: 133:205925
 TITLE: **PR39**, a peptide regulator of angiogenesis. [Erratum to document cited in CA132:149677]
 AUTHOR(S): Li, Jian; Post, Mark; Volk, Rudiger; Gao, Youhe; Li, Min; Metals, Caroline; Sato, Kaori; Tsai, Jo; Aird, William; Rosenberg, Robert D.; Hampton, Thomas G.; Li, Jianyi; Sellke, Frank; Carmeliet, Peter; Simons, Michael
 CORPORATE SOURCE: Angiogenesis Research Center, Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, 02215, USA
 SOURCE: Nature Medicine (New York) (2000), 6(3), 356
 CODEN: NAMEFI; ISSN: 1078-8956
 PUBLISHER: Nature America
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The correct versions are given for Figs. 2a, c, and d on page 51; Fig. 3c on page 52; and Fig. 5b on page 53.
 IT 139637-11-9, **PR-39**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (PR39 peptide in regulation of angiogenesis by inhibiting ubiquitin-proteasome-dependent degrdn. of hypoxia-inducible factor-1.alpha. protein (Erratum))
 RN 139637-11-9 HCAPLUS
 CN L-Prolinamide, L-arginyl-L-arginyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-prolyl-L-tyrosyl-L-leucyl-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-prolyl-L-arginyl-L-leucyl-L-prolyl-L-prolyl-L-arginyl-L-isoleucyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-prolyl-L-arginyl-L-phenylalanyl-L-prolyl-L-arginyl-L-phenylalanyl-L-prolyl-L-arginyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L8 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:46162 HCAPLUS
 DOCUMENT NUMBER: 132:149677
 TITLE: **PR39**, a peptide regulator of angiogenesis
 AUTHOR(S): Li, Jian; Post, Mark; Volk, Rudiger; Gao, Youhe; Li, Min; Metals, Caroline; Sato, Kaori; Tsai, Jo; Aird, William; Rosenberg, Robert D.; Hampton, Thomas G.; Li, Jianyi; Sellke, Frank; Carmeliet, Peter; Simons, Michael
 CORPORATE SOURCE: Angiogenesis Research Center, Department of Surgery both at Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, 02215, USA
 SOURCE: Nature Medicine (New York) (2000), 6(1), 49-55
 CODEN: NAMEFI; ISSN: 1078-8956
 PUBLISHER: Nature America
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Although tissue injury and inflammation are considered essential for the induction of angiogenesis, the mol. controls of this cascade are mostly unknown. Here we show that a macrophage-derived peptide,

THIS PAGE BLANK (USPTO)

PR39, inhibited the ubiquitin-proteasome-dependent degrdn. of hypoxia-inducible factor-1.alpha. protein, resulting in accelerated formation of vascular structures in vitro and increased myocardial vasculature in mice. For the latter, coronary flow studies demonstrated that **PR39**-induced **angiogenesis** resulted in the prodn. of functional blood vessels. These findings show that **PR39** and related compds. can be used as potent inductors of **angiogenesis**, and that selective inhibition of hypoxia-inducible factor-1.alpha. degrdn. may underlie the mechanism of inflammation-induced **angiogenesis**.

IT 139637-11-9, **PR-39**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**PR39** peptide in regulation of **angiogenesis** by inhibiting ubiquitin-proteasome-dependent degrdn. of hypoxia-inducible factor-1.alpha. protein)

RN 139637-11-9 HCPLUS

CN L-Prolinamide, L-arginyl-L-arginyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-prolyl-L-tyrosyl-L-leucyl-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-prolyl-L-phenylalanyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-leucyl-L-prolyl-L-arginyl-L-isoleucyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-phenylalanyl-L-prolyl-L-arginyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 6 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:357168 HCPLUS

DOCUMENT NUMBER: 125:26311

TITLE: Synducin (syndecan expression-inducers) mediate modulation of tissue repair

INVENTOR(S): Gallo, Richard L.; Bernfield, Merton

PATENT ASSIGNEE(S): Children's Medical Center Corporation, USA

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9609322	A2	19960328	WO 1995-US12080	19950922
WO 9609322	A3	19960523		
W: AU, CA, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5654273	A	19970805	US 1994-310722	19940922
AU 9538228	A1	19960409	AU 1995-38228	19950922
US 5863897	A	19990126	US 1996-728333	19961010
PRIORITY APPLN. INFO.:			US 1994-310722	19940922
			WO 1995-US12080	19950922

AB The membrane-permeating antibacterial peptide, **PR-39**, previously found only in the intestine, was purified from wound fluid and shown to possess syndecan-1 and syndecan-4 inductive activity specifically in mesenchymal cells. This is a newly recognized function that defines

THIS PAGE BLANK 100%

peptide contg. syndecan-inducing activity, and that are known as synducins. Therefore, a mol. with both antimicrobial and synducin activities is deposited in wounds where it can simultaneously reduce infection and the influence the action of growth factors, matrix components, and other cellular effectors involved in wound repair. Synducins, including PR-39, and derivs. thereof, as well as other proline and arginine-rich antimicrobial peptides, collectively referred to herein as "synducins", are therefore useful in the modulation of wound healing, as well as other disorders involving mesenchymal cells and cell surface mol. interaction, including metastatic disease, angiogenesis, restenosis, stasis or decubitis ulcers, and prevention of keloids.

IT

139637-11-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(synducins are syndecan expression-inducing peptides that mediate modulation of mesenchymal tissue repair)

RN

139637-11-9 HCPLUS

CN

L-Prolinamide, L-arginyl-L-arginyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-prolyl-L-tyrosyl-L-leucyl-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-prolyl-L-phenylalanyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-leucyl-L-prolyl-L-prolyl-L-arginyl-L-isoleucyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

THIS PAGE BLANK (USPTO)

4 Protein - protein search, using SW model			
on:	May 13, 2003, 10:32:27 ; Search time 35 Seconds (without alignments)	in:	57.107 Million cell updates/sec
title:	US-09-426-011D-3	perfect score:	90
sequence:	1. RRRPRPPYLPRPRPP 15	scoring table:	BLOSUM62
gap:	Gapext 0.5	gap:	Gapext 0.5
searched:	908470 seqs, 133230620 residues	total number of hits satisfying chosen parameters:	908470
minimum DB seq length:	0	maximum DB seq length:	2000000000
post-processing:	Minimum Match 0%	Maximum Match 100%	Listing First 45 summaries
database :	<p>A_GeneSeq_101002,* 1: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1980.DAT :* 2: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1981.DAT :* 3: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1982.DAT :* 4: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1983.DAT :* 5: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1984.DAT :* 6: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1985.DAT :* 7: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1986.DAT :* 8: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1987.DAT :* 9: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1988.DAT :* 10: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1989.DAT :* 11: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1990.DAT :* 12: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1991.DAT :* 13: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1992.DAT :* 14: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1993.DAT :* 15: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1994.DAT :* 16: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1995.DAT :* 17: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1996.DAT :* 18: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1997.DAT :* 19: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1998.DAT :* 20: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA1999.DAT :* 21: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA2000.DAT :* 22: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA2001.DAT :* 23: /SIDS2/gcgdata/geneseqp-geneseqp-emb1/AA2002.DAT :*</p>	alignments	alignments
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.	<p>RESULT 1 AAB26885 ID AAB26885 standard; peptide; 15 AA. XX AC AAB26885; XX DT 01-FEB-2001 (first entry) XX DE PR-39 derived angiogenesis regulatory peptide 1. XX KW Angiogenesis; stimulation; PR-39; anoxia; myocardial infarction; XX KW myocardial ischaemia; proteasome. XX OS Synthetic. XX PN WO20057895-A1. XX PD 05-OCT-2000. XX PP 16-MAR-2000; 2000WO-US07050. XX PR 26-MAR-1999; 99US-0276868. XX PA (BETH ISRAEL DEACONNESS MEDICAL CENT. XX PI Simons M, Gao Y; XX PA DR WPI: 2000-628319/60. XX DR XX Stimulating angiogenesis in situ, useful e.g. for treating anoxia and infarction, by administering a PR-39 oligopeptide that regulates PT enzymatic activity of proteosomes - XX Macrinin peptide a Macrinin peptide a</p>	summaries	summaries
result No.	Score	Query Match Length	DB ID Description
1	90	100.0	15 21 AAB26885 PR-39 derived angi
2	90	100.0	15 22 AAB84691 Amino acid sequenc
3	90	100.0	15 22 AAB97277 PR-39 derived peptide
4	90	100.0	19 17 AAW01452 Leukocyte O2- prod
5	90	100.0	26 17 AAW01447 Leukocyte O2- prod
6	90	100.0	26 19 AAW75723 Proline/Arginine r
7	90	100.0	39 14 AAR30491 Anti-bacterial pept
8	90	100.0	39 17 AAW01446 Leukocyte O2- prod
9	90	100.0	39 17 AAR99121 Macrinin peptide a
10	90	100.0	39 17 AAR99121 Macrinin peptide a

PS Claim 12; Page 40; 51pp; English.
 XX This invention relates to a method for the stimulation of angiogenesis in
 CC situ within a targeted collection of viable cells. The method comprises in
 CC introducing, into the cytoplasm, at least 1 member of the PR-39
 CC oligopeptide collective, which interacts with cytoplasmic proteasomes.
 CC Part of the proteolytic activity of the proteosomes is selectively
 CC altered so as to stimulate angiogenesis. The method is used to induce
 CC angiogenesis in tissue that has suffered anoxia or infarction,
 CC e.g. myocardial infarction or chronic myocardial ischaemia, and also to
 CC study the mechanisms that control angiogenesis. The present sequence
 CC represents a PR-39 derived peptide which interacts with the proteosome
 CC and can be used in the method of the invention.
 XX Sequence 15 AA;

Query Match 100.0%; Score 90; DB 22; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.0002;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 RRRPRPPYLPRPRPP 15
 Db 1 RRRPRPPYLPRPRPP 15

RESULT 2
 AAB84691
 ID AAB84691. standard; peptide; 15 AA.
 XX
 AC AAB84691;
 XX
 DT 17-SEP-2001 (first entry)
 XX
 DB Amino acid sequence of a PR-39 derived peptide (residues 1-15).
 XX
 PR-39; IkappaBalpha degradation; NFkappaB transcription factor;
 XX myocardial infarction; chronic myocardial ischaemia; heart disease;
 XX anoxia.
 XX Unidentified.
 XX WO200147540-A1.
 XX
 PD 05-JUL-2001.
 XX
 PF 27-DEC-2000; 2000WO-US335293.
 XX 29-DEC-1999; 99US-0474967.
 XX (BETH-) BETH ISRAEL DEACONESS MEDICAL CENT.
 XX
 PI Simons M, Gao Y;
 XX
 DR WPI; 2001-355179/37.
 XX
 PS Claim 12; Page 42; 52pp; English.

XX Peptides AAB97277 - AAB97279 represent PR-39 derived oligopeptides. PR-39
 CC is a member of the the catheelin family of proteins. mature PR-39 is 39
 CC amino acids in length (see AAB97280), and has been shown to play a role
 CC in several inflammatory events including wound healing and myocardial
 CC infarction. The PR-39 derived family of oligopeptides cause selective
 CC inhibition of proteasome mediated degradation of proteins and
 CC stimulation of angiogenesis after their intracellular introduction to a
 CC target cell. PR-39 derived peptides are able to interact with at least
 CC the alpha7 subunit of the proteasomes, and therefore alter the
 CC proteolytic activity of proteasomes such that a selective increased
 CC expression of specific proteins occurs. The invention includes methods
 CC for the selective inhibition of proteasome mediated peptide degradation.
 CC The method provides means for stimulating angiogenesis as required in
 CC living tissues and organs which have suffered defects or have undergone
 CC anoxia and/or infarction. myocardial infarction or chronic myocardial
 CC ischaemia of heart tissue. Examples are the myocardium, skeleton or
 CC smooth muscle, artery or vein, lung, brain, kidney, spleen, liver,
 CC gastrointestinal or nerve tissues, limbs, and extremities. A particular
 XX example is after myocardial infarction or ischaemia.
 XX Sequence 15 AA;

Query Match 100.0%; Score 90; DB 22; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.0002;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 RRRPRPPYLPRPRPP 15

Query Match 100.0%; Score 90; DB 22; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.0002;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 RRRPRPPYLPRPRPP 15
 Db 1 RRRPRPPYLPRPRPP 15

RESULT 3
 AAB97277
 ID AAB97277 standard; peptide; 15 AA.
 XX
 AC AAB97277;
 XX
 AC AAB97277;
 XX
 DT 09-AUG-2001 (first entry)
 XX
 DE PR-39 derived peptide PR-15.
 XX
 KW PR-39; catheelin; inflammation; wound healing; myocardial infarction;
 KW proteasome; proteopeptide; alpha7; Peptide; angiogenesis;
 KW anoxia; chronic myocardial ischaemia; heart tissue.
 XX
 OS Unidentified.
 XX
 PN WO200130368-A1.
 XX
 PD 03-MAY-2001.
 XX
 PF 06-OCT-2000; 2000WO-US27552.
 XX
 PR 25-OCT-1999; 99US-0426011.
 XX
 PA (BETH-) BETH ISRAEL DEACONESS MEDICAL CENT.
 XX
 PI Simons M, Gao Y;
 XX
 DR WPI; 2001-355179/37.
 XX
 PS Claim 12; Page 42; 52pp; English.

Peptides AAB97277 - AAB97279 represent PR-39 derived oligopeptides. PR-39
 CC is a member of the the catheelin family of proteins. mature PR-39 is 39
 CC amino acids in length (see AAB97280), and has been shown to play a role
 CC in several inflammatory events including wound healing and myocardial
 CC infarction. The PR-39 derived family of oligopeptides cause selective
 CC inhibition of proteasome mediated degradation of peptides and
 CC stimulation of angiogenesis after their intracellular introduction to a
 CC target cell. PR-39 derived peptides are able to interact with at least
 CC the alpha7 subunit of the proteasomes, and therefore alter the
 CC proteolytic activity of proteasomes such that a selective increased
 CC expression of specific proteins occurs. The invention includes methods
 CC for the selective inhibition of proteasome mediated peptide degradation.
 CC The method provides means for stimulating angiogenesis as required in
 CC living tissues and organs which have suffered defects or have undergone
 CC anoxia and/or infarction. myocardial infarction or chronic myocardial
 CC ischaemia of heart tissue. Examples are the myocardium, skeleton or
 CC smooth muscle, artery or vein, lung, brain, kidney, spleen, liver,
 CC gastrointestinal or nerve tissues, limbs, and extremities. A particular
 XX example is after myocardial infarction or ischaemia.
 XX Sequence 15 AA;

Query Match 100.0%; Score 90; DB 22; Length 15;
 Best Local Similarity 100.0%; Pred. No. 0.0002;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 RRRPRPPYLPRPRPP 15

Db ||||| RRRPRPPYLPRPRPP 15
 AC AAW01447;
 XX DT 18-JUN-1997 (first entry)

RESULT 4
 AAW01452 standard; peptide; 19 AA.
 ID AAW01452.
 XX AC AAW01452;
 XX DT 18-JUN-1997 (first entry)
 XX DE Leukocyte O2- production inhibitor peptide PR26.
 XX KW Inhibitor; leukocyte O2- production; proline-arginine rich peptide; pig;
 XX KW antimicrobial peptide; small intestine; human; neutrophil; bacteria;
 XX DNA synthesis; protein synthesis; inhibitor; syndecan expression;
 XX mesenchymal cell; wound repair; superoxide anion; infection; leukocyte;
 XX tissue damage; oxygen radical; inflammatory disease; therapy.
 XX OS Synthetic.
 XX PN WO9632129-A1.
 XX XX
 XX PD 17-OCT-1996.
 XX PP 10-APR-1996; 96WO-US04674.
 XX PR 10-APR-1995; 95US-0419066.
 XX PA (UNIV) UNIV KANSAS STATE RES FOUND.
 XX PI Blecha F, Shi J;
 XX DR WPI: 1996-476842/47.
 XX PT Inhibition of leukocyte superoxide anion prodn. and attraction of
 XX leukocytes - using peptide(s) partic. based on antimicrobial PR-39
 XX PS Claim 3; Page 26; 45pp; English.
 XX CC AAW01447-W01454 represent fragments of the proline-arginine rich
 XX antimicrobial peptide PR39 (see AAW01446). The PR39 sequence was first
 XX isolated from porcine small intestine. It has also been identified in
 XX human and porcine neutrophils. PR39 kills bacteria by interfering with
 XX DNA and/or protein synthesis. PR39 also induces syndecan expression on
 XX mesenchymal cells. Syndecans are important in wound repair, showing that
 XX PR39 can be used in wound repair, as well as in antibacterial agents.
 XX These sequences, and PR39, can be used in the method of the invention.
 XX The method of the invention is for inhibiting leukocyte superoxide anion
 XX CC production. The method comprises administering to a leukocyte a
 XX peptide (such as this sequence) capable of inhibiting leukocyte superoxide anion
 XX CC production. The peptides can be used as medicaments for fighting
 XX CC infection by attracting leukocytes to a wound site and restricting
 XX CC tissue damage at the wound site caused by excessive oxygen radicals
 XX CC produced by these leukocytes. They can also be used to develop products
 XX CC for treating inflammatory disease states.
 XX SQ Sequence 26 AA;
 XX DR Query Match 100.0%; Score 90; DB 17; Length 26;
 XX Best Local Similarity 100.0%; Pred. No. 0.00033; Pred. No. 0.00033;
 XX Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX PT Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 Oy 1 RRRPRPPYLPRPRPP 15
 Db 1 RRRPRPPYLPRPRPP 15
 RESULT 5
 AAW01447 standard; peptide; 26 AA.
 ID AAW01447
 XX AC AAW01447 standard; peptide; 26 AA.
 XX DE Proline/Arginine rich peptide PR-26.
 XX KW Proline; arginine; peptide; reperfusion injury; neutrophil; endothelium;
 XX superoxide; neutrophil superoxide anion; chemotaxis; NADPH oxidase;

KW	coronary bypass; organ transplantation surgery.	PN	WO9222578-A.
XX		XX	23-DEC-1992.
OS	Synthet. C.	PD	
XX	WO9835690-A1.	XX	10-JUN-1992;
XX		XX	92WO-SE00394.
PD	20-AUG-1998.	PR	14-JUN-1991;
XX	17-FEB-1998; 9800-US03207.	XX	91SE-0001838.
PF		PA	(BOMA/) BOMAN H G.
XX		PA	(JOER/) JOERNVALL H.
PR	16-FEB-1998; 98US-0024975.	PA	(LIEU/) LEE J.
PR	18-FEB-1997; 97US-0802305.	PA	(MUTT/) MUTT V.
XX	(UNIV) UNIV KANSAS STATE RES FOUND.	XX	Boman HG, Joernvall H, Lee J, Matt V;
XX	Blecha F, Ross CR, Shi J;	PI	
XX	WPI; 1998-495359/42.	XX	WPI; 1993-018080/02.
XX	DR	XX	New anti-bacterial polypeptide - active against Gram negative
PT	Reduction of reperfusion injury in temporarily occluded blood vessels - by administration of a peptide which is rich in proline or arginine residues	PT	PT bacteria
PT	Claim 3; Page 14-15; 35pp; English.	PS	Claim 1; Page 10; 15pp; English.
XX	Sequences AA75722-W75732 are proline/arginine rich peptides that upon administration into a mammal's bloodstream reduce reperfusion injury (production of reactive oxygen species, neutrophil adherence to endothelium, and extravasation of neutrophils). These peptides have two requirements: they contain the consensus sequence PXXP, where P is a proline residue and X is any amino acid residue, which has been found to inhibit superoxide production, and secondly they have arginine residues adjacent to these motifs, required for effective inhibition. It was established by structural and function analysis that a peptide should ideally contain 4 or 6 of these motifs, and that inhibitory activity is correlated with the increase of length of peptides. The effectiveness of these peptides was determined by investigating the production of the neutrophil superoxide anion, and also the inhibition of neutrophil chemotaxis. From this, it was found that all of the peptides inhibited NADPH oxidase to some extent. All of the peptides also inhibit neutrophil oxidase activity. PR-39 is believed, to be the most potent endogenous down regulator of NADPH oxidase yet discovered, and from the data produced, it can be suggested to be involved in eliminating or reducing the reperfusion injury induced adhesion and extraction of neutrophils. The peptides are also useful in connection with surgical procedures such as, coronary bypass and organ transplantation surgery.	XX	This peptide was isolated from the small intestine of a pig. The small intestine is an important endocrine organ and many physiologically active peptides have been isolated from it. This peptide inhibits the growth of, and may kill, bacteria, pref. gram negative bacteria. This peptide or its functional derivatives may be used in human or veterinary medicine for therapeutic or prophylactic use.
XX	Sequence 26 AA;	SQ	Sequence 39 AA;
XX	Query Match 100.0%; Score 90; DB 19; Length 39;	Query Match 100.0%; Score 90; DB 14; Length 39;	
XX	Best Local Similarity 100.0%; Pred. No. 0.00033;	Best Local Similarity 100.0%; Pred. No. 0.00047;	
XX	Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
AC	AAR30491. standard peptide; 39 AA.	Qy 1 RRRPRPPYLPRPPPP 15	Qy 1 RRRPRPPYLPRPPPP 15
AC	AAR30491;	Db 1 RRRPRPPYLPRPPPP 15	Db 1 RRRPRPPYLPRPPPP 15
XX	12-MAY-1993 (first entry)	XX	18-JUN-1997 (first entry)
XX	Antibacterial peptide.	DE	Leukocyte O ₂ - production inhibitor peptide PR39.
XX	KW	XX	Inhibitor; leukocyte O ₂ - production; proline-arginine rich peptide; pig;
XX	KW	XX	antimicrobial peptide; small intestine; human; neutrophil; bacteria;
XX	KW	XX	DNA synthesis; protein synthesis; inhibitor; syndecan expression;
XX	KW	XX	mesenchymal cell; wound repair; superoxide anion; infection; leukocyte; tissue damage; oxygen radical; inflammatory disease; therapy.
XX	OS	XX	Synthetic.
XX	W09632129-A1.	XX	
XX	10-APR-1996;	PN	96WO-US04674.
XX	10-APR-1995;	PD	95US-0419066.
XX	(UNIV) UNIV KANSAS STATE RES FOUND.	PA	
XX	Blecha F, Shi J;	PI	
XX	DR	XX	WPI; 1996-476842/47.
XX	Sus scrofa domestica.	XX	

PT Inhibition of leukocyte super:oxide anion prodn. and attraction of
 PT leukocytes - using peptide(s) partic. based on antimicrobial PR-39
 XX Claim 2; Page 26; 45pp; English.

XX This sequence represents the proline-arginine rich antimicrobial peptide
 CC PR39. The PR39 sequence was first isolated from porcine small intestine,
 CC and has also been identified in human and porcine neutrophils. PR39
 CC kills bacteria by interfering with DNA and/or Protein synthesis. PR39
 CC also induces syndecan expression on mesenchymal cells. Syndecans are
 CC important in wound repair, showing that PR39 can be used in wound repair,
 CC as well as in antibacterial agents. This sequence, and the fragments of
 CC it shown in AAW01447, W01454, can be used in the method of the invention.
 CC The method of the invention method comprises administering to a leukocyte a
 CC (O2-) production. The method comprises administering to a leukocyte a
 CC peptide (such as this sequence) capable of inhibiting leukocyte O2-
 CC production. The peptides can be used as medicaments for fighting
 CC infection by attracting leukocytes to a wound site and restricting tissue
 CC damage at the wound site caused by excessive oxygen radicals produced by
 CC these leukocytes. They can also be used to develop products for treating
 CC inflammatory disease states.

XX Sequence 39 AA;

Query Match 100.0%; Score 90; DB 17; Length 39;
 Best Local Similarity 100.0%; Pred. No. 0.00047; Indels 0; Gaps 0;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RRRPRPPYLPRPRPP 15
 Db 1 RRRPRPPYLPRPRPP 15

RESULT 9
 AAR94446
 ID AAR94446 standard; peptide; 39 AA.
 XX
 AC AAR94446;
 XX DT 05-NOV-1996 (first entry)
 XX DB synduin peptide (PR-39) induces syndecan expression.
 XX KW Synduin; induction; expression; syndecan-1; syndecan-4; surface;
 KW mesenchymal cell; fibroblast; epithelial; PR-39; treatment; stasis;
 KW decubitus; ulcers; keloids; skin burns; ischemic tissues;
 KW hypercoagulation states; prevention; tumour metastasis; restenosis;
 KW inhibition; angiogenesis; proliferation; endothelial.
 OS Synthetic.
 XX PN WO960322-A2.
 XX PR 22-SEP-1994; 94US-0310722.
 XX PA (CHIL-) CHILDRENS MEDICAL CENT.
 XX PI Bernfield M, Gallo RL;
 XX DR 1996-188401/19.

XX Modulating mesenchymal interaction by administration of synduin

PT used in the treatment of wounds, tumours, restenosis, etc

XX Claim 4; Page 26; 34pp; English.

XX The present peptide is a synduin, which induces the expression of
 CC syndecan-1 and syndecan-4 on the surface of mesenchymal cells, esp.
 CC fibroblasts and epithelial cells. The 36 N-terminal amino acids of
 CC

CC the peptide were found to be identical to the 36 N-terminal amino
 CC acids of PR-39, a Pro and Arg rich antimicrobial peptide previously
 CC found in porcine intestine (WO922278). Synducins may be used in
 CC the treatment of stasis and decubitus ulcers, keloids, skin burns,
 CC ischemic tissues and hypercoagulation states; prevention of tumour
 CC metastasis, restenosis inhibition and endothelial cell angiogenesis
 CC and proliferation induction.
 CC Human microvascular endothelial cells were assayed for syndecan-4
 CC expression following exposure to 5 % wound fluid, dbcAMP (1 mM),
 CC the present peptide (10 microm) or a blank, to give respective
 CC cell surface syndecan-4 values (mO/m in) of approx. 1.75, 1.70,
 CC 1.80 and 0.95.
 XX Sequence 39 AA;

Query Match 100.0%; Score 90; DB 17; Length 39;
 Best Local Similarity 100.0%; Pred. No. 0.00047;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RRRPRPPYLPRPRPP 15
 Db 1 RRRPRPPYLPRPRPP 15

RESULT 10
 AAR99121
 ID AAR99121 standard; peptide; 39 AA.
 AC AAR99121;
 XX DT 28-OCT-1996 (first entry)
 XX DE Magainin-derived antimicrobial STD-inhibiting peptide, MSI-1312.
 XX STD; sexually transmitted disease; HIV; human immunodeficiency virus;
 KW herpes simplex virus; HSV; Neisseria gonorrhoeae; Candida; Chlamydia;
 KW magainin; antimicrobial; squalamine.
 XX OS Synthetic.
 XX PH Key
 FT Modified-site
 FT /note= "amidated"
 XX PN WO9608270-A2.
 XX PD 21-MAR-1996.
 XX PF 13-SEP-1995; 95WO-US11675.
 XX PR 13-SEP-1994; 94US-0305475.
 XX PA (MAGA-) MAGAININ PHARM INC.
 XX PI Bedi G, Jacob L, Williams T, Zasloff M;
 XX DR WPI; 1996-17975/18.
 XX PT Inhibiting sexually transmitted disease e.g. HIV or herpes simplex -
 PT by administering magainin antimicrobial or squalamine cpd. to
 PT inhibit transmission.

XX Example 1; Page 32; 60pp; English.
 CC AAR99116-R99123 are antimicrobial, magainin-analogue peptides that may
 CC be used to treat sexually transmitted diseases (STDs) caused by
 CC Chlamydia, HIV, herpes simplex virus, Neisseria gonorrhoeae or
 CC Candida infection. The peptides inhibit STDs by either killing the
 CC infectious organism, impeding the infection mechanism or
 CC interrupting the replication cycle of the organism. Squalamine (an
 CC aminosterol host defence molecule of the dog fish shark Squalus
 CC acanthias) and PGLa (a frog antimicrobial peptide) analogues may
 CC also be useful in inhibiting STD infection and transmission.

XX Sequence 39 AA;

XX Query Match 100.0%; Score 90; DB 17; Length 39;

XX Best Local Similarity 100.0%; Pred. No. 0.0007;

XX Matches 15; Conservative 0; Mismatches 0;

XX Indels 0; Gaps 0;

Qy 1 RRRPRPPYLPRPRPP 15

Db 1 RRRPRPPYLPRPRPP 15

RESULT 11

AAW75722 standard; peptide; 39 AA.

XX ID AAW75722;

XX AC AAW75722;

XX DT 19-NOV-1998 (first entry)

XX DE Proline/Arginine rich Peptide PR-39.

XX KW Proline; arginine; peptide; reperfusion injury; neutrophil; endothelium; superoxide; neutrophil superoxide anion; chemotaxis; NADPH oxidase; coronary bypass; organ transplantation surgery.

XX OS Synthetic.

XX WO9835690-A1.

XX PN WO9835690-A1.

XX PD 20-AUG-1998.

XX PP 17-FEB-1998; 98WO-US03207.

XX PR 16-FEB-1998; 98US-0024975.

XX PR 18-FEB-1997; 97US-08023006.

XX PA (UNIV) UNTV KANSAS STATE RES FOUND.

XX PI Blecha P, ROSS CR, Shi J;

XX WPI: 1998-495359/42.

XX Reduction of reperfusion injury in temporarily occluded blood vessels - by administration of a peptide which is rich in proline or arginine residues

XX PT Claim 3; Page 14; 35pp; English.

XX Sequences AAW75722-W75732 are proline/arginine rich peptides that upon administration into a mammal's blood/areum reduce reperfusion injury (production of reactive oxygen species, neutrophil adherence to endothelium, and extravasation of neutrophils). These peptides have two requirements: they contain the consensus sequence PXXP, where P is a proline residue and X is any amino acid residue, which has been found to inhibit superoxide production, and secondly they have arginine residues adjacent to these motifs, required for effective inhibition. It was established by structural and function analysis that a peptide should ideally contain 4 or 6 of these motifs, and that inhibitory activity is correlated with the increase of length of peptides. The effectiveness of these peptides was determined by investigating the production of the neutrophil superoxide anion, and also the inhibition of neutrophil chemotaxis. From this, it was found that all of the peptides inhibited NADPH oxidase to some extent. PR-39 is believed, to be the most potent neutrophil oxidase activity. PR-39 is believed, to be the most potent endogenous down regulator of NADPH oxidase yet discovered, and from the data produced, it can be suggested to be involved in eliminating or reducing the reperfusion injury induced adhesion and extraction of neutrophils. The peptides are also useful in connection with surgical procedures such as coronary bypass and organ transplantation surgery.

XX Sequence 39 AA;

XX Query Match 100.0%; Score 90; DB 19; Length 39;

XX Best Local Similarity 100.0%; Pred. No. 0.00047;

XX Matches 15; Conservative 0; Mismatches 0;

XX Indels 0; Gaps 0;

Qy 1 RRRPRPPYLPRPRPP 15

Db 1 RRRPRPPYLPRPRPP 15

RESULT 12

AAB26888 standard; peptide; 39 AA.

XX ID AAB26888;

XX AC AAB26888;

XX DT 01-FEB-2001 (first entry)

XX DE PR-39 peptide used in angiogenesis control.

XX KW Angiogenesis; stimulation; PR-39; anoxia; myocardial infarction; myocardial ischaemia; proteasome.

XX OS Synthetic.

XX PN WO200057895-A1.

XX PD 05-OCT-2000.

XX PP 16-MAR-2000; 2000WO-US07050.

XX PR 26-MAR-1999;

XX PA (BETH) BETH ISRAEL DEACNESS MEDICAL CENT.

XX PT Stimulating angiogenesis in situ, useful e.g. for treating anoxia and infarction, by administering a PR-39 oligopeptide that regulates enzymatic activity of proteosomes

XX Disclosure: Page 21; 51pp; English.

XX This invention relates to a method for the stimulation of angiogenesis in situ within a targeted collection of viable cells. The method comprises introducing, into the cytoplasm, at least 1 member of the PR-39 oligopeptide collective, which interacts with cytoplasmic proteasomes. Part of the proteolytic activity of the proteasomes is selectively altered so as to stimulate angiogenesis. The method is used to induce angiogenesis in tissue that has suffered anoxia or infarction, e.g. myocardial infarction or chronic myocardial ischaemia, and also to study the mechanisms that control angiogenesis. The present sequence represents the PR-39 peptide from which peptide used in the method of the invention are derived.

XX Sequence 39 AA;

XX Query Match 100.0%; Score 90; DB 21; Length 39;

XX Best Local Similarity 100.0%; Pred. No. 0.00047;

XX Matches 15; Conservative 0; Mismatches 0;

XX Indels 0; Gaps 0;

Qy 1 RRRPRPPYLPRPRPP 15

Db 1 RRRPRPPYLPRPRPP 15

RESULT 13

AAB84630 standard; protein; 39 AA.

XX ID AAB84630;

XX AC AAB84630;

PI	Fritz J.	Mattner F.	Zauner W.	Buschle M.	Egyed A.
XX	1111	2222	3333	4444	5555

WPL: 2002-269154/31.

Vaccine for active immunization or for preparing an adjuvant for enhancing an immune response to at least one antigen, comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide -

Diagnosis: Fig 3: 6500: English

The invention relates to a vaccine comprising at least one antigen and at least one cathelicidin derived antimicrobial peptide or its derivative. The vaccine is useful for active immunization, especially of humans or animals without protection against the specific antigen. The cathelicidin derived antimicrobial peptide is useful in the preparation of an adjuvant for enhancing the immune response to at least one antigen, where the adjuvant enhances the uptake of at least one antigen in antigen presenting cells (APC), and the adjuvant is added to the vaccine. Sequences ABB0708-15 represent C-terminal fragments of antimicrobial peptides of the cathelicidin family.

Sequence 42 AA:

```

Query Match      100.0%;  Score 90;  DB 23;  Length 42;
Best Local Similarity 100.0%;  Pred. No. 0.0005;
Matches 15;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0;
Qy   1 RRRPRPPYLPRRP 15
Db   1 RRRPRPPYLPRRP 15

```

Search completed: May 13, 2003, 10:40:32
Job time : 36 SECS

GenCore version 5.1.4.p5 4578
 Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 13, 2003, 10:40:17 ; Search time 14 Seconds

(without alignments)

31.525 Million cell updates/sec

Title: US-09-426-011D-3

Perfect score: 90

Sequence: 1 RRRRPPYLPYRPRPP 15

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 262574 seqs, 29422922 residues

Total number of hits satisfying chosen parameters: 262574

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing First 45 summaries

Database : Issued_Patents_A:*

1: /cgn2_6/ptodata/1/iaa/5A_COMB.pep:*

2: /cgn2_6/ptodata/1/iaa/5B_COMB.pep:*

3: /cgn2_6/ptodata/1/iaa/6A_COMB.pep:*

4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep:*

5: /cgn2_6/ptodata/1/iaa/PCT05_Comb.pep:*

6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the total score distribution, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	90	100.0	26	2 US-09-419-066-2	Sequence 2, Appli
2	90	100.0	26	4 US-09-024-975-2	Sequence 2, Appli
3	90	100.0	39	1 US-08-162-052-1	Sequence 1, Appli
4	90	100.0	39	1 US-08-310-722-1	—
5	90	100.0	39	2 US-08-419-066-1	Sequence 1, Appli
6	90	100.0	39	2 US-08-728-333-1	Sequence 1, Appli
7	90	100.0	39	4 US-09-024-975-1	Sequence 1, Appli
8	90	100.0	39	5 PCT-US95-12050-1	Sequence 1, Appli
9	83	92.2	14	4 US-09-024-975-4	Sequence 9, Appli
10	66	73.3	20	4 US-09-024-975-9	Sequence 1, Appli
11	61	67.8	336	1 US-08-414-9264-26	Sequence 26, Appli
12	61	67.8	336	2 US-08-926-922-26	Sequence 26, Appli
13	61	67.8	336	3 US-09-253-682-26	Sequence 26, Appli
14	61	67.8	336	4 US-09-527-657-26	Sequence 26, Appli
15	59	65.6	59	5 PCT-US95-12050-3	Sequence 3, Appli
16	53	58.9	18	1 US-08-205-938A-23	Sequence 23, Appli
17	53	58.9	18	1 US-08-205-938A-24	Sequence 24, Appli
18	53	58.9	18	4 US-09-220-180-20	Sequence 20, Appli
19	53	58.9	18	5 PCT-US95-02626-23	Sequence 23, Appli
20	53	58.9	18	5 PCT-US95-02626-24	Sequence 24, Appli
21	52	57.8	18	1 US-08-205-938A-25	Sequence 25, Appli
22	52	57.8	18	5 PCT-US95-02626-25	Sequence 25, Appli
23	51.5	57.2	355	4 US-08-483-533-41	Sequence 41, Appli
24	51.5	57.2	355	4 US-09-233-471A-41	Sequence 41, Appli
25	51.5	57.2	355	5 PCT-US91-06532-3	Sequence 3, Appli
26	51	56.7	16	1 US-08-205-938A-8	Sequence 8, Appli
27	51	56.7	16	5 PCT-US95-02626-8	Sequence 8, Appli

ALIGNMENTS

RESULT 1

US-08-419-066-2

; Sequence 2, Application US/08419066

; Patent No. 5830993

; GENERAL INFORMATION:

; APPLICANT: Blecha, Frank

; TITLE OF INVENTION: SYNTHETIC ANTIMICROBIAL PEPTIDE

; NUMBER OF SEQUENCES: 2

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: John M. Collins, Hovey, Williams, Timmons &

; STREET: 2405 Grand Boulevard, Suite 400

; CITY: Kansas City

; STATE: Missouri

; COUNTRY: U.S.A.

; ZIP: 64108

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/419,066

; FILING DATE:

; CLASSIFICATION: 530

; ATTORNEY/AGENT INFORMATION:

; NAME: Collins, John M.

; REGISTRATION NUMBER: 26262

; REFERENCE/DOCKET NUMBER: 23625

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (816) 474-9050

; TELEFAX: (816) 474-9057

; INFORMATION FOR SEQ ID NO: 2:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 26 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: Peptide

; HYPOTHETICAL: NO

; ANTI-SENSE: NO

; FRAGMENT TYPE: N-terminal

; US-08-419-066-2:

; Query Match 100.0%

; Best Local Similarity 100.0%

; Pred. No. 6.2e-05;

; Mismatches 0;

; Indels 0;

; caps 0;

; Qy 1 RRRRPPYLPYRPRPP 15

Db 1 |||||RRRPRPPYLPRPRPP 15

RESULT 2

US-09-024-975-2 Application US/09024975

Patent No. 613233

GENERAL INFORMATION

APPLICANT: ROSS, CHRISTOPHER R.

APPLICANT: BLECHA, FRANK

APPLICANT: SHI, JISHU

TITLE OF INVENTION: PEPTIDE MODULATION OF REPERFUSION INJURY

NUMBER OF SEQUENCES: 11

CORRESPONDENCE ADDRESS:

ADDRESSEE: HOVEY, WILLIAMS, TIMMONS & COLLINS

STREET: 2405 GRAND BLVD., SUITE 400

CITY: KANSAS CITY

STATE: MO

COUNTRY: USA

ZIP: 64108

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent In Release #1.0, Version #1.3.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/024,975

FILED DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/802,306.

FILED DATE: 18 FEB 1997

ATTORNEY/AGENT INFORMATION:

NAME: COLLINS, JOHN M.

REGISTRATION NUMBER: 26,262

REFERENCE/DOCKET NUMBER: 25595-A

TELEPHONE: 816/474-9050

TELEFAX: 816/474-9057

INFORMATION FOR SEQ ID NO: 2:

SEQUENCE CHARACTERISTICS:

TYPE: amino acid

LENGTH: 26 amino acids

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-09-024-975-2

Query Match 100.0%; Score 90; DB 4; Length 26;

Best Local Similarity 100.0%; Pred. No. 6.2e-05;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RRRPRPPYLPRPRPP 15

Db 1 RRRPRPPYLPRPRPP 15

RESULT 3

US-08-162-052-1 Application US/08162052

Patent No. 5488575

GENERAL INFORMATION

APPLICANT: LEE, Jong-Youn

APPLICANT: BOMAN, Hans G

APPLICANT: MOTT, Viktor

APPLICANT: JORNAVALL, Hans

TITLE OF INVENTION: NOVEL POLYPEPTIDES AND THEIR USE

NUMBER OF SEQUENCES: 1

CORRESPONDENCE ADDRESS:

ADDRESSEE: Burris, Doane, Swecker & Mathis

STREET: P.O. Box 1404

CITY: Alexandria

STATE: Virginia

Qy 1 RRRPRPPYLPRPRPP 15

Db 1 RRRPRPPYLPRPRPP 15

Query Match 100.0%; Score 90; DB 1; Length 39;

Best Local Similarity 100.0%; Pred. No. 9.1e-05;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RRRPRPPYLPRPRPP 15

Db 1 RRRPRPPYLPRPRPP 15

RESULT 4

US-08-310-722-1 Application US/08310722

Patent No. 5654273

GENERAL INFORMATION

APPLICANT: GALLO, Richard L.

APPLICANT: Klagsbrun, Michael

TITLE OF INVENTION: Synducin Mediated Modulation of Tissue Repair

NUMBER OF SEQUENCES: 1

CORRESPONDENCE ADDRESS:

ADDRESSEE: Patrea L. Pabst

STREET: 1100 Peachtree Street, Suite 2800

CITY: Atlanta

STATE: Georgia

ZIP: 30309-4530

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent In Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/310,722

FILED DATE: 22-SEP-1994

CLASSIFICATION: 424

ATTORNEY/AGENT INFORMATION:

NAME: Pabst, Patrea L.

REGISTRATION NUMBER: 31,284

REFERENCE/DOCKET NUMBER: CMCC379

TELECOMMUNICATION INFORMATION:

TELEPHONE: (404) -815-6508

TELEFAX: (404)-815-6555
 SEQUENCE CHARACTERISTICS:
 LENGTH: 39 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 ANTI-SENSE: NO
 PUBLICATION INFORMATION:
 AUTHORS: Lee, Jong-Youn
 Boman, Hans G.
 AUTHORS: Mutt, Viktor
 AUTHORS: Jornvall, Hans
 TITLE: NO. 5654273el Polypeptides And Their Use
 JOURNAL: PCT WO 92/22578
 DATE: 12/23/92
 RELEVANT RESIDUES IN SEQ ID NO: 1: FROM 1 TO 39
 US-08-310-722-1

Query Match 100.0%; Score 90; DB 2; Length 39;
 Best Local Similarity 100.0%; Pred. No. 9.1e-05;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RRRPRPPYLPRPRPP 15
 Db 1 RRRPRPPYLPRPRPP 15

RESULT 5
 US-08-419-066-1
 Sequence 1, Application US/08419066
 ; Patent No. 5830939

GENERAL INFORMATION:
 APPLICANT: Blecha, Frank
 TITLE OF INVENTION: SYNTHETIC ANTIMICROBIAL PEPTIDE
 NUMBER OF SEQUENCES: 2
 CORRESPONDENCE ADDRESS:
 ADDRESSSEE: John M. Collins, Hovey, Williams, Timmons &
 ADDRESS: 2405 Grand Boulevard, Suite 400
 CITY: Kansas City
 STATE: Missouri
 COUNTRY: U.S.A.
 ZIP: 64108

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/419,066
 FILING DATE:
 CLASSIFICATION: 530
 ATTORNEY/AGENT INFORMATION:
 NAME: Collins, John M.
 REGISTRATION NUMBER: 26262
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (816) 474-9050
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 39 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: Peptide
 HYPOTHETICAL: NO
 ANTI-SENSE: NO
 FRAGMENT TYPE: N-terminal
 US-08-419-066-1

Query Match 100.0%; Score 90; DB 2; Length 39;
 Best Local Similarity 100.0%; Pred. No. 9.1e-05;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RRRPRPPYLPRPRPP 15
 Db 1 RRRPRPPYLPRPRPP 15

RESULT 6
 US-08-728-333-1
 Sequence 1, Application US/08728333
 ; Patent No. 5863897

GENERAL INFORMATION:
 APPLICANT: Gallo, Richard L.
 APPLICANT: Klagsbrun, Michael
 TITLE OF INVENTION: Synducin Mediated Modulation of Tissue Repair
 NUMBER OF SEQUENCES: 1

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Patrea L. Pabst
 STREET: 1100 Peachtree Street, Suite 2800
 CITY: Atlanta
 STATE: Georgia
 COUNTRY: USA
 ZIP: 30309-4530

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/728,333
 FILING DATE:
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/310,722
 FILING DATE: 22-SEP-1994
 ATTORNEY/AGENT INFORMATION:
 NAME: Pabst, Patrea L.
 REGISTRATION NUMBER: CMCC379
 FILING DATE: (404)-815-6508
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (404)-815-6555
 TELEFAX: (404)-815-6555
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 39 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 HYPOTHETICAL: NO
 ANTI-SENSE: NO
 PUBLICATION INFORMATION:
 AUTHORS: Lee, Jong-You
 Boman, Hans G.
 AUTHORS: Mutt, Viktor
 AUTHORS: Jornvall, Hans
 TITLE: NO. 5863897el Polypeptides And Their Use
 JOURNAL: PCT WO 92/22578
 DATE: 12/23/92
 RELEVANT RESIDUES IN SEQ ID NO: 1: FROM 1 TO 39
 US-08-728-333-1

Query Match 100.0%; Score 90; DB 2; Length 39;
 Best Local Similarity 100.0%; Pred. No. 9.1e-05;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RRRPRPPYLPRPRPP 15
 Db 1 RRRPRPPYLPRPRPP 15

RESULT 7
 US 09-024-975-1
 Sequence 1, Application US/09024975
 Patent No. 6133233
 GENERAL INFORMATION
 APPLICANT: ROSS, CHRISTOPHER R.
 APPLICANT: BLECHA, FRANK
 APPLICANT: SHI, JIUSHU
 TITLE OF INVENTION: PEPTIDE MODULATION OF REPERFUSION INJURY
 NUMBER OF SEQUENCES: 11
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: HOVEY, WILLIAMS, TIMMONS & COLLINS
 STREET: 2405 GRAND BLVD., SUITE 400
 CITY: KANSAS CITY
 STATE: MO
 COUNTRY: USA
 ZIP: 64108
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/024,975
 FILING DATE:
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/802,306
 FILING DATE: 18-FEB-1997
 ATTORNEY/AGENT INFORMATION:
 NAME: COLLINS, JOHN M.
 REGISTRATION NUMBER: 26-262
 REFERENCE/DOCKET NUMBER: 25585-A
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 816/474-9050
 TELEFAX: 816/474-9057
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 39 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 US 09-024-975-1

Query Match 100.0%; Score 90; DB 4; Length 39;
 Best Local Similarity 100.0%; Pred. No. 9.1e-05; Mismatches 0;
 Indels 0; Gaps 0;

Qy 1 RRRPRPPYLPRPRPP 15
 Db 1 RRRPRPPYLPRPRPP 15

RESULT 8
 PCT-US95-12080-1
 Sequence 1, Application PC/TUS9512080
 GENERAL INFORMATION
 APPLICANT: Children's Medical Center Corporation
 TITLE OF INVENTION: Synducin Mediated Modulation of Tissue Repair
 NUMBER OF SEQUENCES: 4
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Patrea L. Pabst
 STREET: 2800 One Atlantic Center
 CITY: Atlanta
 STATE: Georgia
 ZIP: 30309-3450
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US 08/802,306
 FILING DATE: 18-FEB-1997
 ATTORNEY/AGENT INFORMATION:
 NAME: COLLINS, JOHN M.
 REGISTRATION NUMBER: 26-262
 REFERENCE/DOCKET NUMBER: 25585-A
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 816/474-9050
 TELEFAX: 816/474-9057
 INFORMATION FOR SEQ ID NO: 4:
 SEQUENCE CHARACTERISTICS:

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US 09/024,975
 FILING DATE:
 ATTORNEY/AGENT INFORMATION:
 NAME: SHI, JIUSHU
 REGISTRATION NUMBER:
 CITY: KANSAS CITY
 STATE: MO
 COUNTRY: USA
 ZIP: 64108
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/024,975
 FILING DATE:
 ATTORNEY/AGENT INFORMATION:
 NAME: ROSS, CHRISTOPHER R.
 REGISTRATION NUMBER:
 CITY: KANSAS CITY
 STATE: MO
 COUNTRY: USA
 ZIP: 64108
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25

LENGTH: 14 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 US-09-024-975-4

Query Match 92.2%; Score 83; DB 4; Length 14;
 Best Local Similarity 100.0%; Pred. No. 0.00023; Number of Sequences: 27
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Country: USA
 ZIP: 94306-2155
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/414,926A
 FILING DATE: March 31, 1995
 ATTORNEY/AGENT INFORMATION:
 NAME: Ceiri, Luann
 REGISTRATION NUMBER: 31,822
 REFERENCE/DOCKET NUMBER: AVTR-011/00TS
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 415-494-7622
 TELEFAX: 415-857-0663
 INFORMATION FOR SEQ ID NO: 26:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 336 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 IMMEDIATE SOURCE:
 CLONE: to1.22
 FEATURE:
 NAME/KEY: Protein
 LOCATION: 1..336
 OTHER INFORMATION: /label= U151;

US-08-414-926A-26

Query Match 67.8%; Score 61; DB 1; Length 336;
 Best Local Similarity 78.6%; Pred. No. 1.7%; Number of Sequences: 3;
 Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2 RRRPRPYLPQRPP 15
 Db 279 RRPPIPQLQQRPP 292

RESULT 12
 US-08-926-922-26

Sequence 26, Application US/08926922
 Patent No. 5925751
 GENERAL INFORMATION:
 APPLICANT: Spete, Richard
 TITLE OF INVENTION: NOVEL HUMAN CYTOMEGALOVIRUS
 NUMBER OF SEQUENCES: 27
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Luann Cser, Attorney at Law
 STREET: 750 Arimo Avenue
 CITY: Oakland
 STATE: CA
 COUNTRY: USA
 ZIP: 94610
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/926,922

RESULT 11
 US-08-414-976A-26
 Sequence 26, Application US/08414926A
 Patent No. 5721354
 GENERAL INFORMATION:

FILING DATE: September 10, 1997
 CLASSIFICATION: 536
 ATTORNEY/AGENT INFORMATION:
 NAME: Cserr, Luann
 REGISTRATION NUMBER: 31,822
 REFERENCE/DOCKET NUMBER: AAVIR 11A
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 510-834-1448
 TELEX/FAX: 510-839-7810
 INFORMATION FOR SEQ ID NO: 26:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 336 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 IMMEDIATE SOURCE:
 CLONE: t01.22

FEATURE:
 NAME/KEY: Protein
 OTHER INFORMATION: /label= U1151
 US-08-926-922-26

Query Match 67.8%; Score 61; DB 2; Length 336;
 Best Local Similarity 78.6%; Pred. No. 1.7;
 Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2 RRRPPYLPRPRPP 15
 Db 279 RRPPIPLQRPRP 292

RESULT 13
 US-09-253-682-26

Sequence 26, Application US/09253682
 Patent No. 6040170

GENERAL INFORMATION:
 Spaele, Richard
 APPLICANT: Cha, Tai-An
 APPLICANT: Spaele, Richard
 APPLICANT: Cha, Tai-An
 TITLE OF INVENTION: NOVEL HUMAN CYTOMEGALOVIRUS
 NUMBER OF SEQUENCES: 27
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Luann Cserr Attorney at Law
 STREET: 750 Arimo Avenue
 CITY: Oakland
 STATE: CA
 COUNTRY: USA
 ZIP: 94610

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/527,657
 FILING DATE: 17-Mar-2000
 CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US/08/926,922
 FILING DATE: September 10, 1997
 ATTORNEY/AGENT INFORMATION:
 NAME: Cserr, Luann
 REGISTRATION NUMBER: 31,822
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 510-834-1448
 INFORMATION FOR SEQ ID NO: 26:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 336 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 IMMEDIATE SOURCE:
 CLONE: t01.22

FEATURE:
 NAME/KEY: Protein
 LOCATION: 1..316
 OTHER INFORMATION: /label= U1151
 US-09-527-682-26

Query Match 67.8%; Score 61; DB 4; Length 336;
 Best Local Similarity 78.6%; Pred. No. 1.7;
 Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2 RRRPPYLPRPRPP 15

Dh 279 BBPT1.QBPP 292

Search completed: May 13, 2003, 10:42:08
Job time: 15:00:00

THIS PAGE BLANK (USPTO)

GenCore version 5.1.4 p5 4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 13, 2003, 10:40:37 ; Search time 17 Seconds
(without alignments)
81.199 Million cell updates/sec

Title: US-09-426-011D-3

Perfect score: 90

Sequence: 1 RRRRPPYPLPRPRP 15

Scoring table: BLOSUM62

Gapext 0.0 , Gapext 0.5

Searched: 349150 seqs, 92025710 residues

Total number of hits satisfying chosen parameters: 349150

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing First 45 summaries

Database : Published Applications AA:*

- 1: /cgn2_6/peodata/2/pubpa/us08 NEW PUB.PEP:*
- 2: /cgn2_6/peodata/2/pubpa/PCT.PUB.NEW_PUB.PEP:*
- 3: /cgn2_6/peodata/2/pubpa/us06 NEW PUB.PEP:*
- 4: /cgn2_6/peodata/2/pubpa/us07_PUBCOMB.PEP:*
- 5: /cgn2_6/peodata/2/pubpa/us07_NBW.PUB.PEP:*
- 6: /cgn2_6/peodata/2/pubpa/us07_PUBCOMB.PEP:*
- 7: /cgn2_6/peodata/2/pubpa/PCTUS_PUBCOMB.PEP:*
- 8: /cgn2_6/peodata/2/pubpa/us08_PUBCOMB.PEP:*
- 9: /cgn2_6/peodata/2/pubpa/us09 NEW PUB.PEP:*
- 10: /cgn2_6/peodata/2/pubpa/us09_PUBCOMB.PEP:*
- 11: /cgn2_6/peodata/2/pubpa/us10_NBW_PUB.PEP:*
- 12: /cgn2_6/peodata/2/pubpa/us10_PUBCOMB.PEP:*
- 13: /cgn2_6/peodata/2/pubpa/us60_NEW PUB.PEP:*
- 14: /cgn2_6/peodata/2/pubpa/us60_PUBCOMB.PEP:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	66	73.3	59	10 US-09-030-619-163	Sequence 163, App
2	60	66.7	953	10 US-09-088-615-66	Sequence 66, App
3	56.5	62.8	74	10 US-09-064-761-45555	Sequence 45555, A
4	55	61.1	45	10 US-09-064-761-450965	Sequence 49055, A
5	54	60.0	250	9 US-10-102-806-517	Sequence 517, App
6	53	58.9	18	10 US-09-030-619-96	Sequence 619, App
7	53	58.9	18	10 US-09-030-619-158	Sequence 158, App
8	53	58.9	18	10 US-09-030-619-159	Sequence 159, App
9	52	57.8	18	10 US-09-030-619-160	Sequence 160, App
10	52	57.8	354	9 US-10-004-717-2	Sequence 2, App
11	52	57.8	354	9 US-10-004-717-58	Sequence 5, App
12	51	56.7	180	10 US-09-097-701-5	Sequence 5, App
13	51	56.7	195	10 US-09-097-701-1	Sequence 1, App
14	50.5	56.1	392	10 US-09-747-835A-55	Sequence 55, App
15	50.5	56.1	393	9 US-10-243-035-2	Sequence 2, App
16	50.5	56.1	419	10 US-09-828-035-2	Sequence 2, App
17	50.5	56.1	1314	10 US-09-747-835A-29	Sequence 29, App
18	50	55.6	99	10 US-09-614-761-43778	Sequence 43778, A
19	50	55.6	146	9 US-09-989-920-237	Sequence 237, App

ALIGNMENTS

RESULT 1
US-09-030-619-163
; Sequence 163, Application US/09030619B
; Patent No. US2002035061A1
; GENERAL INFORMATION:
; APPLICANT: Krieger, Timothy J.
; APPLICANT: Taylor, Robert
; APPLICANT: Erfle, Douglas
; APPLICANT: Fraser, Janet R.
; APPLICANT: West, Michael H.P.
; APPLICANT: McNicol, Patricia J.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING
; CAPTOMIC PEPTIDES ALONE OR IN COMBINATION
; WITH ANTIBIOTICS
; FILE REFERENCE: 660081-406
; CURRENT APPLICATION NUMBER: US/09/030,619B
; CURRENT FILING DATE: 1998-02-25
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO: 163
; LENGTH: 59
; TYPE: PRT
; ORGANISM: Bos taurus
US-09-030-619-163

Query Match 73.3%; Score 66; DB 10;
Best Local Similarity 85.7%; Pred. No. 0.27;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 RRRPRPPYLPRPRP 14
Db 2 RIRPRPRPLRPRP 15

RESULT 2
US-09-888-615-66
; Sequence 66, Application US/09888615
; Patent No. US2002064856A1
; GENERAL INFORMATION:
; APPLICANT: Plowman, Gregory
; APPLICANT: Whyte, David
; APPLICANT: Caenpeel, Sean

Patent No. US20020035061A1
 GENERAL INFORMATION:
 APPLICANT: Krieger, Timothy J.
 APPLICANT: Taylor, Robert
 APPLICANT: Erie, Douglas
 APPLICANT: Fraser, Janet R.
 APPLICANT: West, Michael H.P.
 APPLICANT: McNicol, Patricia J.
 TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING
 INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION
 WITH ANTIBIOTICS
 FILE REFERENCE: 660081-406
 CURRENT APPLICATION NUMBER: US/09/030,619B
 CURRENT FILING DATE: 1998-02-25
 NUMBER OF SEQ ID NOS: 232
 SOFTWARE: FastSEQ for Windows Version 3.0
 SEQ ID NO 96
 LENGTH: 45
 TYPE: PRT
 ORGANISM: Homo sapiens
 FEATURE:
 OTHER INFORMATION: MAP TO ACO05973.2
 OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 0.88
 OTHER INFORMATION: EST_HUMAN HIT: AI358103.1, EVALU 4.60e+00
 US-09-864-761-49065
 LENGTH: 45
 TYPE: PRT
 ORGANISM: Homo sapiens
 FEATURE:
 OTHER INFORMATION: EST_HUMAN HIT: AI358103.1, EVALU 4.60e+00
 SEQ ID NO 96
 LENGTH: 45
 TYPE: PRT
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Cationic Peptide Analogue
 US-09-030-619-96
 LENGTH: 18
 TYPE: PRT
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Cationic Peptide Analogue
 US-09-030-619-96
 LENGTH: 18
 Query Match 58.9%; Score 53; DB 10; Length 18;
 Best Local Similarity 72.7%; Pred. No 2.6;
 Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 Qy 5 RPPYLPRRPP 15
 Db 4 RPVYIPQPRPP 14
 RESULT 7
 US-09-030-619-158
 Sequence 158, Application US/09030619B
 CURRENT APPLICATION NUMBER: US/09030619B
 CURRENT FILING DATE: 1998-02-25
 NUMBER OF SEQ ID NOS: 232
 SOFTWARE: FastSEQ for Windows Version 3.0
 SEQ ID NO 13
 LENGTH: 18
 TYPE: PRT
 ORGANISM: Homo sapiens
 FEATURE:
 OTHER INFORMATION: Sequence 517, Application US/10102806
 Publication No. US20030054421A1
 GENERAL INFORMATION:
 APPLICANT: Rosen et al.
 TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
 FILE REFERENCE: PA103P1C1
 CURRENT APPLICATION NUMBER: US/10/102,806
 CURRENT FILING DATE: 2002-03-22
 NUMBER OF SEQ ID NOS: 846
 SOFTWARE: PatentIn Ver. 2.0
 SEQ ID NO 517
 LENGTH: 250
 TYPE: PRT
 ORGANISM: Homo sapiens
 FEATURE:
 NAME/KEY: SITE
 LOCATION: (118)
 OTHER INFORMATION: xaa equals any of the naturally occurring L-amino acids
 US-10-102-806-517
 LENGTH: 18
 Query Match 58.9%; Score 53; DB 10; Length 18;
 Best Local Similarity 72.7%; Pred. No 2.6;
 Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 Qy 5 RPPYLPRRPP 15
 Db 4 RPVYIPQPRPP 14
 RESULT 8
 US-09-030-619-159
 Sequence 159, Application US/09030619B
 CURRENT APPLICATION NUMBER: US/09030619B
 CURRENT FILING DATE: 1998-02-25
 NUMBER OF SEQ ID NOS: 232
 SOFTWARE: FastSEQ for Windows Version 3.0
 SEQ ID NO 13
 LENGTH: 18
 TYPE: PRT
 ORGANISM: Apis mellifera
 US-09-030-619-158
 LENGTH: 18
 Query Match 58.9%; Score 53; DB 10; Length 18;
 Best Local Similarity 72.7%; Pred. No 2.6;
 Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 Qy 5 RPPYLPRRPP 15
 Db 4 RPVYIPQPRPP 14
 RESULT 6
 US-09-030-619-96
 Sequence 96, Application US/09030619B
 CURRENT APPLICATION NUMBER: US/09030619B
 CURRENT FILING DATE: 1998-02-25
 NUMBER OF SEQ ID NOS: 232
 SOFTWARE: FastSEQ for Windows Version 3.0
 SEQ ID NO 13
 LENGTH: 18
 TYPE: PRT
 ORGANISM: Apis mellifera
 US-09-030-619-159
 LENGTH: 18
 Query Match 58.9%; Score 53; DB 10; Length 18;
 Best Local Similarity 72.7%; Pred. No 2.6;
 Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

RESULT 9
US-09-030-619-160
; Sequence 160, Application US/09030619B
; GENERAL INFORMATION:
; APPLICANT: Krieger, Timothy J.
; APPLICANT: Erflie, Douglas
; APPLICANT: Fraser, Janet R.
; APPLICANT: McNicol, Patricia J.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING
; INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION
; TITLE OF INVENTION: INFECTIONS WITH ANTIOTIOTICS
; FILE REFERENCE: 660081.406
; CURRENT APPLICATION NUMBER: US/09/030,619B
; CURRENT FILING DATE: 1998-02-25
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 159
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Apis mellifera
US-09-030-619-159

Query Match 58.9%; Score 53; DB 10; Length 18;
Best Local Similarity 72.7%; Pred. No. 2.6;
Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
Db 5 RPYYLPRPRPP 15
Qy 4 RPYYIPQPRPP 14

RESULT 10
US-10-004-717-2
; Sequence 2, Application US/10004717
; Publication No. US201020192665A1
; GENERAL INFORMATION:
; APPLICANT: ZOGHBI, HUDA Y.
; APPLICANT: YANG, QI
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE OF AN
; ATOML ASSOCIATED SEQUENCE FOR DEAFNESS, OSTEOARTHRITIS, AND ABNORMAL CELL PROLIFERATION
; FILE REFERENCE: P01899154
; CURRENT APPLICATION NUMBER: US/10/004,717
; CURRENT FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: 09/585,645
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: 60/176,993
; PRIOR FILING DATE: 2000-01-19
; PRIOR APPLICATION NUMBER: 60/137,060
; PRIOR FILING DATE: 1998-06-01
; NUMBER OF SEQ ID NOS: 69
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 354
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-004-717-2

Query Match 57.8%; Score 52; DB 9; Length 354;
Best Local Similarity 57.1%; Pred. No. 52;
Matches 8; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
Db 5 RPYYLPRPRPP 15
Qy 4 RPYYIPQPRPP 14

RESULT 11
US-10-004-717-58
; Sequence 58, Application US/10004717
; Publication No. US201020192665A1
; GENERAL INFORMATION:
; APPLICANT: ZOGHBI, HUDA Y.
; APPLICANT: YANG, QI
; TITLE OF INVENTION: ATOML ASSOCIATED SEQUENCE FOR DEAFNESS, OSTEOARTHRITIS, AND ABNORMAL CELL PROLIFERATION
; FILE REFERENCE: P01899154
; CURRENT APPLICATION NUMBER: US/10/004,717
; CURRENT FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: 09/585,645
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: 60/176,993
; PRIOR FILING DATE: 2000-01-19
; PRIOR APPLICATION NUMBER: 60/137,060
; PRIOR FILING DATE: 1998-06-01
; NUMBER OF SEQ ID NOS: 69
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 58
; LENGTH: 354
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-004-717-58

Query Match 57.8%; Score 52; DB 9; Length 354;
Best Local Similarity 57.1%; Pred. No. 52;
Matches 8; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
Db 5 RPYYLPRPRPP 15
Qy 4 RPYYIPQPRPP 14

RESULT 12
US-09-997-701-5
; Sequence 5, Application US/09997701
; Publication No. US200920107180A1
; GENERAL INFORMATION:
; APPLICANT: Yue, Henry
; APPLICANT: Corley, Neil C.
; APPLICANT: Guegler, Karl J.
; APPLICANT: Gorgone, Gina A.
; APPLICANT: Baughn, Mariah R.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE OF AN
; ATOML ASSOCIATED SEQUENCE FOR DEAFNESS, OSTEOARTHRITIS, AND ABNORMAL CELL PROLIFERATION
; FILE REFERENCE: P01899054

CURRENT APPLICATION NUMBER: US/09/997,701
 CURRENT FILING DATE: 2001-11-30
 PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 09/470,946
 NUMBER OF SEQ ID NOS: 6
 SOFTWARE: PERL Program
 SEQ ID NO 5
 LENGTH: 180
 TYPE: PRT
 ORGANISM: Homo sapiens
 OTHER INFORMATION: g2499136
 US-09-997-701-5

Query Match Similarity 56.7%; Pred. No. 36; Score 51; DB 10; Length 180;
 Best Local Similarity 53.8%; Matches 3; Mismatches 3; Indels 0; Gaps 0;
 SOFTWARE: PERL Program
 SEQ ID NO 5
 LENGTH: 180
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-09-997-701-1

RESULT 13

US-09-997-701-1
 Sequence 1, Application US/09997701
 Patent No. US20020107180A1
 GENERAL INFORMATION:
 APPLICANT: Yue, Henry
 APPLICANT: Corley, Neil C.
 APPLICANT: Guegler, Karl J.
 APPLICANT: Gorgone, Gina A.
 APPLICANT: Baughn, Mariah R.
 TITLE OF INVENTION: CELL SURFACE GLYCOPROTEINS
 FILE REFERENCE: PP-0631 US

CURRENT APPLICATION NUMBER: US/09/997,701
 CURRENT FILING DATE: 2001-11-30
 PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 09/470,946
 NUMBER OF SEQ ID NOS: 6
 SOFTWARE: PERL Program
 SEQ ID NO 1
 LENGTH: 195
 TYPE: PRT
 ORGANISM: Homo sapiens
 OTHER INFORMATION: 2297891
 US-09-997-701-1

Query Match Similarity 56.7%; Pred. No. 36; Score 51; DB 10; Length 180;
 Best Local Similarity 53.8%; Matches 3; Mismatches 3; Indels 0; Gaps 0;
 SOFTWARE: PERL Program
 SEQ ID NO 5
 LENGTH: 180
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-09-997-701-5

RESULT 14

US-09-997-701-5
 Sequence 55, Application US/09747835A
 Patent No. US20020146692A1
 GENERAL INFORMATION:
 APPLICANT: Yamazaki, Victoria
 APPLICANT: Tang, Y. Tom
 APPLICANT: Liu, Chenghua
 APPLICANT: Zhou, Ping
 APPLICANT: Wang, Dunrui
 APPLICANT: Zhang, Jie
 APPLICANT: Ren, Feiyi
 APPLICANT: Asundi, Vinod
 APPLICANT: Drmanac, Radivoje T
 TITLE OF INVENTION: METHODS AND MATERIALS RELATING TO G PROTEIN-COUPLED RECEPTOR-LIKE

Query Match Similarity 56.1%; Pred. No. 85; Score 50.5%; Length 392;
 Best Local Similarity 68.8%; Matches 11; Mismatches 4; Indels 1; Gaps 1;
 US-09-747-835A-55

RESULT 15

US-10-243-035-2
 Sequence 2, Application US/10243035
 Publication No. US20030049637A1
 GENERAL INFORMATION:
 APPLICANT: LAZDUNSKI, MICHAEL
 APPLICANT: LESAIS, FLORIAN
 APPLICANT: MAINCRET, FRANCOIS
 TITLE OF INVENTION: NEW FAMILY OF MECHANOSENSITIVE HUMAN POTASSIUM CHANNELS
 TITLE OF INVENTION: ACTIVATED BY POLYUNSATURATED FATTY ACIDS AND THEIR USE
 FILE REFERENCE: 1317-02
 CURRENT APPLICATION NUMBER: US/10/243,035
 CURRENT FILING DATE: 2002-09-13
 NUMBER OF SEQ ID NOS: 15
 SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO 2
 LENGTH: 393
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-10-243-035-2

Query Match Similarity 56.1%; Pred. No. 85; Score 50.5%; Length 393;
 Best Local Similarity 68.8%; Matches 11; Mismatches 4; Indels 1; Gaps 1;

Qy 1 RRRPPPPYLP-RPRPP 15
 Db 368 RRRPNPCKVPRKPRGP 383

Search completed: May 13, 2003, 10:42:32
 Job time : 18 secs

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

GenCore version 5.1.4 p5-4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model
Run on: May 13, 2003, 10:38:17 ; Search time 16 Seconds
90.126 Million cell updates/sec (without alignments)

Title: US-09-426-011D-3
Perfect score: 90
Sequence: 1 RRRPPPPYPLPRPRPP 15

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283224 seqs, 96134422 residues

Total number of hits satisfying chosen parameters: 2832224

Minimum DB seq length: 0
Maximum DB seq length: 20000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 73;*
1: pir1;*
2: pir2;*
3: pir3;*
4: pir4;*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match	Length	DB ID	Description
1	90	100.0	172	2	66232	antimicrobial protein bactenecin 7 - bovine
2	66	73.3	59	2	A36589	spore coat protein
3	59	66.1	82	2	A41051	antimicrobial peptide
4	58	64.4	190	2	S68330	apidaecin 14 precursor
5	56.5	62.8	168	2	S35330	extensin class I protein R13D1.3 [
6	56.5	62.8	199	2	A4981	hybrid proline-rich
7	55	61.1	437	2	A88942	hypothetical protein
8	54.5	60.6	301	2	JQ1663	hypothetical protein
9	54	60.0	359	2	T13478	hypothetical protein
10	54	60.0	427	2	T32632	hypothetical protein
11	53	58.9	26	2	S06675	apidaecin 1b precursor
12	53	58.9	144	2	S35331	apidaecin 22 precursor
13	53	58.9	184	2	T29373	hypothetical protein
14	53	58.9	283	2	S35312	apidaecin 73 precursor
15	53	58.9	428	2	E7115	probable cell wall protein
16	53	58.9	491	2	T07538	proline-rich protein
17	52	57.8	261	1	WMBBXE	infected cell protein
18	52	57.8	439	2	S51339	chitinase (BC 3.2.1.54)
19	52	57.8	467	2	S71159	protein kinase, 54
20	52	57.8	1006	2	G86232	hypothetical protein
21	51.5	57.2	1187	1	JC4155	protein in tyrosine-P
22	51.5	57.2	1189	1	JC2366	protein in tyrosine-P
23	51	56.7	180	2	S43791	PDX protein - human
24	50	56.1	1216	2	JW0105	synaptosomal 2 alp
25	50	55.6	192	2	S76867	hypothetical protein
26	50	55.6	383	2	T06753	zinc finger protein
27	50	55.6	415	1	S32170	acrosin (BC 3.4.21)
28	50	55.6	421	2	S29559	acrosin (BC 3.4.21)
29	50	55.6	424	2	A54954	spliceosome-associated

ALIGNMENTS

RESULT 1
S68232 antimicrobial protein PR-39 precursor, cathelin-associated - pig
N;Alternate names: myeloid antibacterial protein PR-39
C;Species: *Sus scrofa domesticus* (domestic Pig)
C;Date: 15-Feb-1997 #sequence revision 13-Mar-1997 #text_change 20-Jun-2000
C;Accession: S68232; JN0899; T47138; S15963
FBBS Lett. 376, 130-134, 1995
A;Title: Structures of genes for two cathelin-associated antimicrobial peptides: propheni
A;Reference number: S68232; MUID:96105365; PMID:7498526
A;Accession: S68232
A;Status: translation not shown
A;Molecule type: DNA
A;Residues: 1-172 <ZFA>
A;Cross-references: EMBL:X89201; NID:91165150; PIDN:CAA61487.1; PID:gi1165151
A;Experimental source: leukocytes
R;Storici, P.; Zanetti, M.
Biochem. Biophys. Res. Commun. 196, 1058-1065, 1993
A;Title: A cDNA derived from pig bone marrow cells predicts a sequence identical to the j
A;Reference number: JN0899; MUID:94071853; PMID:8250863
A;Accession: JN0899
A;Molecule type: mRNA
A;Residues: 1-20 / A / 22-172 <STO>
A;Cross-references: GB:L23825; NID:9435100; PID:9435101
A;Experimental source: bone marrow cells
R;Gudmundsson, G.H.; Magnusson, K.P.; Chowdhury, B.P.; Johansson, M.; Andersson, L.; Bome
Proc. Natl. Acad. Sci. U.S.A. 92, 7085-7089, 1995
A;Title: Structure of the gene for porcine peptide antibiotic PR-39, a cathelin gene fami
A;Reference number: I47138; MUID:9550216; PMID:724374
A;Accession: I47138
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-28 / T / 30-89 'OR' 92-116 'NDP' 120-172 <GUD>
A;Cross-references: EMBL:X87236; NID:989142; PIDN:CAA60682.1; PID:gi1051298
R;Agerberth, B.; Lee, J.Y.; Bergman, T.; Carlquist, M.; Nutt, H.G.; Nutt, V.; Joernvall,
Eur. J. Biochem. 202, 849-854, 1991
A;Title: Amino acid sequence of PR-39. Isolation from pig intestine of a new member of t
A;Reference number: S19563
A;Accession: S19563
A;Molecule type: protein
A;Residues: 131-169 <AGE>
A;Experimental source: intestine
C;Genetics:
A;Gene: PR39
A;Introns: 66/3: 102/3: 126/3
C;Superfamily: cathalin; cystatin homology
C;Keywords: amidated carboxyl end; antibacterial
F:1-29/Domain: signal sequence #status predicted <SIG>
F:22-129/Domain: cystatin homology <CYSS>
F:30-130/Domain: propeptide #status predicted <PRO>
F:131-169/Product: antimicrobial protein PR-39 #status experimental <MAT>

P;169/Modified site: amidated carboxyl end (Pro) (amide in mature form from following 91

Query Match Score 90; DB 2; Length 172;
Best Local Similarity 100.0%; Prd. No. 0.00035; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RRRPRPPYLPRPPRPP 15
Db 131 RRRPRPPYLPRPPRPP 145

RESULT 2
A3589
bactenecin 7 - bovine
C:Species: Bos primigenius taurinus (cow)
C:Date: 12-Apr-1991 #sequence_revision 12-Apr-1991 #text_change 09-May-1997
C:Accession: A36589
R;Frank, R. W.; Gennaro, R.; Schneider, K.; Przybylski, M.; Romeo, D.
J. Biol. Chem. 265, 1871-1874, 1990
A;Title: Amino acid sequences of two proline-rich bactenecins. Antimicrobial peptides of
A;Reference number: A3589; MUID:91055404; PMID:2223048
A;Accession: A36589
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-59 <FRA>
A;Superfamily: cathelin; cystatin homology

Query Match Score 73.3%; DB 2; Length 59;
Best Local Similarity 85.7%; Pred. No. 0.086; Mismatches 2; Indels 0; Gaps 0;

Qy 1 RRRPRPPYLPRPPRPP 14
Db 2 RRRPRPPYLPRPPRPP 15

RESULT 3
A1051
spore coat protein precursor - *Bacillus subtilis*
C:Species: *Bacillus subtilis*
C:Date: 03-Apr-1992 #sequence_revision 06-Jan-1995 #text_change 11-Jan-2002
C:Accession: S04835; A41051; F69006
R;Aronson, A.I.; Song, H.Y.; Bourne, N.
Mol. Microbiol. 3, 437-444, 1989
A;Title: Gene structure and precursor processing of a novel *Bacillus subtilis* spore coat
A;Reference number: S04835; MUID:8913296; PMID:2546006
A;Molecule type: DNA
A;Residues: 'MNVHTPNLSSIRNMVKGKIKKAREVFL', 2-82 <AR2>
A;Cross-references: EMBL:XA13740; NID:939864; PMID:CA32004.1; PID:939865
A;Experimental source: strain JH642
A;Reference number: A1051; MUID:1917883
A;Accession: A41051
A;Molecule type: protein
A;Residues: 'XX', 3-11 <BO>
A;Experimental source: strain JH642
A;Note: part of this sequence, including the amino end of the mature protein, was confirm

R;Kunst, F.; Ogasawara, N.; Moser, I.; Albertini, A.M.; Alloni, G.; Azevedo, V.; Better, C.; Bron, S.; Brouillet, S.; Bruschi, C.V.; Caldwell, B.; Capuano, V.; Carter, N.M.; Chodat, P.; Ehrlich, S.D.; Ermenson, P.T.; Eutinian, K.D.; Errington, J.; Fabret, C.; Ferrari, B.; Nature 390, 249-256, 1997
A;Authors: Fougeron, D.; Fritz, C.; Fujita, M.; Fujita, Y.; Fuma, S.; Galizzi, A.; Galler, J.; Harwood, C.R.; Henaut, A.; Hilbert, H.; Hollsappel, S.; Hull, M.F.; Koetter, P.; Konigstein, G.; Krogh, S.; Kumano, M.; Kurita, S.; Lapidot, S.; Lardinois, A.; Levine, A.; Liu, H.; Masuda, S.; Mauel, Y.; Moga, K.; Ogiwara, A.; Oudega, V.; Lee, S.M.; Levine, A.; Liu, H.; Pohl, T.M.; Portelle, R.; Rieger, M.; Rivolta, C.; Rocha, E.; Rocha, B.; Rose, M.; Sadaie, Y.; Sato, T.; Scanlon, A.; Authors: Schleich, S.; Schroeber, R.; Scoffone, F.; Sekiguchi, J.; Sekowska, A.; Seron, J.

A;Note: the material sequenced was the larger of two isolated precursor forms; the amino acid sequence of the smaller form was identical to the larger form except for a deletion of the first 14 amino acids.
R;Note: both the location of the transcription start site and peptide sequencing of the amino acid sequence of the smaller form were used to confirm the larger form.
R;Kunst, F.; Ogasawara, N.; Moser, I.; Albertini, A.M.; Alloni, G.; Azevedo, V.; Better, C.; Bron, S.; Brouillet, S.; Bruschi, C.V.; Caldwell, B.; Capuano, V.; Carter, N.M.; Chodat, P.; Ehrlich, S.D.; Ermenson, P.T.; Eutinian, K.D.; Errington, J.; Fabret, C.; Ferrari, B.; Nature 390, 249-256, 1997
A;Authors: Fougeron, D.; Fritz, C.; Fujita, M.; Fujita, Y.; Fuma, S.; Galizzi, A.; Galler, J.; Harwood, C.R.; Henaut, A.; Hilbert, H.; Hollsappel, S.; Hull, M.F.; Koetter, P.; Konigstein, G.; Krogh, S.; Kumano, M.; Kurita, S.; Lapidot, S.; Lardinois, A.; Levine, A.; Liu, H.; Masuda, S.; Mauel, Y.; Moga, K.; Ogiwara, A.; Oudega, V.; Lee, S.M.; Levine, A.; Liu, H.; Pohl, T.M.; Portelle, R.; Rieger, M.; Rivolta, C.; Rocha, E.; Rocha, B.; Rose, M.; Sadaie, Y.; Sato, T.; Scanlon, A.; Authors: Schleich, S.; Schroeber, R.; Scoffone, F.; Sekiguchi, J.; Sekowska, A.; Seron, J.

RESULT 4
S68230
antimicrobial peptide precursor - sheep
N;Alternate names: Bac7.5 peptide homolog
C:Species: Ovis orientalis aries. Ovis ammon aries (domestic sheep)
C:Accession: S68230
R;Bagella, L.; Scocchi, M.; Zanetti, M.
FEBS Lett. 376, 225-228, 1995
A;Title: cDNA sequences of three sheep myeloid cathelicidins.
A;Reference number: S68228; MUID:96105366; PMID:7498547
A;Accession: S68230
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-190

C:Cross-references: EMBL:146852; NID:91161244; PMID:AAA85466.1; PID:91161245
C:Superfamily: cathelin; cystatin homology
P;1-29/Domain: signal sequence #status Predicted <SIG>
P;22-129/Domain: cystatin homology <CYST>
P;29-130/Domain: propeptide #status Predicted <PRO>
P;130-190/Product: antimicrobial peptide #status Predicted <MAT>

Query Match Score 59.5%; DB 2; Length 82;
Best Local Similarity 84.6%; Pred. No. 0.69; Mismatches 0; Indels 1; Gaps 1;

Qy 4 PRPP-YLPYPRPP 15
Db 49 PRPPYYPRPP 61

RESULT 5
S35330
apidaecin 14 precursor - honeybee
N;Contains: apidaecin II
C:Species: Apis mellifera (honeybee)
C:Accession: S35330; S066576
R;Casseele-Josson, K.; Capaci, T.; Casteele, P.; Tempst, P.
C:Title: Apidaecin multipeptide precursor structure: a putative mechanism for amplification
A;Reference number: S35330; MUID:93223657; PMID:8467807
A;Accession: S35330
A;Molecule type: mRNA
A;Residues: 1-168 <CDS>

A;Cross-references: EMBL:X72575; NID:9297062; PIDN:CAA51167.1; PID:9297063
 R;Castells, P.; Ampe, C.; Jacobs, F.; Vaech, M.; Tempst, P.
 EMBO J 8, 2387-2391, 1989
 A;Title: Apidaecins: antibacterial peptides from honeybees.
 A;Reference number: S05383; MUID:9005446; PMID:2676519
 A;Accession: SU6676
 A;Molecule type: protein
 A;Residues: 43-60 <S22>
 C;Superfamily: prokaryotic acidic repetitive protein
 F;43-60/Product: apidaecin II #status experimental <MAT>
 Query Match 62.8%; Score 56.5; DB 2; Length 168;
 Best Local Similarity 50.0%; Pred. No. 3.2;
 Matches 11; Conservative 2; Mismatches 2; Indels 7; Gaps 1;
 Qy 1 RRRP----RPPYPLPRPRPP 15
 Db 117 RREPEAEPGNRNPVYIPLPRPP 138
 RESULT 6
 extein class I (clone w1-8 L) - tomato (fragment)
 C;Species: Lycopersicon esculentum (tomato)
 C;Date: 17-Jul-1998 #sequence_revision 1-Jul-1998 #text_change 11-Jan-2000
 C;Accession: S14981
 R;Showalter, A.M.; Zhou, J.; Rumeau, D.; Worst, S.G.; Varner, J.E.
 Plant Mol. Biol. 16, 547-565, 1991
 A;Title: Tomato extensin and extensin-like cDNAs: structure and expression in response to
 A;Reference number: S14970; MUID:91329690; PMID:1714316
 A;Accession: S14981
 A;Status: preliminary
 A;Molecule type: mRNA
 A;Residues: 1-159 <SH0>
 A;Cross-references: EMBL:X55692
 A;Experimental source: CV: UCG828
 C;Superfamily: hydroxyproline-rich glycoprotein
 C;Keywords: cell wall; glycoprotein; hydroxyproline
 Query Match 62.8%; Score 56.5; DB 2; Length 199;
 Best Local Similarity 73.3%; Pred. No. 3.7;
 Matches 11; Conservative 0; Mismatches 1; Indels 3; Gaps 1;
 Qy 4 PRPP--YLPRPRPP 15
 Db 77 PRPPPEYLPLPRPP 91
 RESULT 7
 protein R13D11.3 [imported] - Caenorhabditis elegans
 C;Species: Caenorhabditis elegans
 C;Date: 10-May-2001 #sequence_revision 10-May-2001 #text_change 10-May-2001
 R;anonymous, The C. elegans Sequencing Consortium.
 Science 282, 2012-2018, 1998
 A;Reference number: A75000; MUID:99069613; PMID:9851916
 A;Note: see websites genome.wustl.edu/gsc/C_elegans/ and www.sanger.ac.uk/Projects/C_elegans/
 A;Accession: A88942
 A;Note: published errata appeared in Science 283, 35, 1999; Science 283, 2103, 1999; and
 A;Cross-references: GB:chr_V; PIDN:AAB69949.1; PID:92384928; GSPDB:GN00023; CESP:R13D11.
 A;Status: preliminary
 A;Molecule type: DNA
 A;Residues: 1-437 <S70>
 A;Cross-references: GB:chr_V; PIDN:AAB69949.1; PID:92384928; GSPDB:GN00023; CESP:R13D11.
 C;Genetics:
 A;Genetics: R13D11.3
 A;Map position: 5
 Query Match 61.1%; Score 55; DB 2; Length 437;
 Best Local Similarity 75.0%; Pred. No. 12;
 Matches 9; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 Qy 4 PRPPYPLPRPRPP 15
 Db 23 PRPPHPIPLPRPP 34
 RESULT 8
 Qy 4 PRPPYPLPRPRPP 15
 Db 23 PRPPHPIPLPRPP 34
 hybrid proline-rich protein - maize
 C;Species: Zea mays (maize)
 C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 24-Sep-1999
 C;Accession: JQ1663
 R;Jose-Estanyol, M.; Ruiz-Avila, L.; Puigdomenech, P.
 Plant Cell 4, 413-423, 1992
 A;Title: A maize embryo-specific gene encodes a proline-rich and hydrophobic protein.
 A;Reference number: JQ1663; MUID:92361259; PMID:1498600
 A;Accession: JQ1663
 A;Molecule type: DNA
 A;Residues: 1-301 <SOS>
 A;Cross-references: EMBL:X60432; NID:9433706; PIDN:CAA44959.1; PID:9433707
 A;Experimental source: strain W64A
 C;Superfamily: hydroxyproline-rich glycoprotein
 C;Genetics:
 Query Match 60.6%; Score 54.5; DB 2; Length 301;
 Best Local Similarity 71.4%; Pred. No. 9.7;
 Matches 10; Conservative 1; Mismatches 2; Indels 1; Gaps 1;
 Qy 3 RPRPPYL-PRPRPP 15
 Db 149 RPSPPVPTPPTPRPP 162
 RESULT 9
 T13478
 hypothetical protein 34F3.10 - fruit fly (Drosophila melanogaster)
 C;Species: Drosophila melanogaster
 C;Date: 13-Aug-1999 #sequence_revision 13-Aug-1999 #text_change 17-Nov-2000
 C;Accession: T13478
 R;Valenti, P.; Salles, C.; Campbell, L.; Glover, D.
 submitted to the EMBL Data Library, April 1999
 A;Description: Sequencing the distal X chromosome of Drosophila melanogaster.
 A;Reference number: Z17685
 A;Accession: T13478
 A;Status: preliminary; translated from GB/EMBL/DDJB
 A;Molecule type: DNA
 A;Residues: 1-359 <PHI>
 A;Cross-references: EMBL:AU031583; NID:e1321005; PID:e1321018; PIDN:CA41346.1
 C;Genetics:
 A;Cross-references: FlyBase:FBgn0025623
 A;Introns: 17/2; 50/3; 333/2
 A;Note: EG:34F3.10
 Query Match 60.0%; Score 54; DB 2; Length 359;
 Best Local Similarity 71.4%; Pred. No. 13;
 Matches 10; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 Qy 2 RPRPPYL-PRPRPP 15
 Db 167 RPRPPPLPPPP 180
 RESULT 10
 T32652
 hypothetical protein F39C12.3 - Caenorhabditis elegans
 C;Species: Caenorhabditis elegans
 C;Date: 29-Oct-1999 #sequence_revision 29-Oct-1999 #text_change 18-Feb-2000
 C;Accession: T32652
 R;Chissoe, S.; Sansone, J.
 submitted to the EMBL Data Library, December 1997
 A;Description: The sequence of C. elegans cosmid F39C12.
 A;Reference number: 221206
 A;Accession: T32652
 A;Status: preliminary; translated from GB/EMBL/DDJB
 A;Molecule type: DNA
 A;Genetics:
 A;Cross-references: GB:chr_V; PIDN:AAB69949.1; PID:92384928; GSPDB:GN00023; CESP:R13D11.
 A;Status: preliminary
 A;Molecule type: DNA
 A;Residues: 1-437 <S70>
 A;Cross-references: GB:chr_V; PIDN:AAB69949.1; PID:92384928; GSPDB:GN00023; CESP:R13D11.
 C;Genetics:
 A;Genetics: R13D11.3
 A;Map position: 5

A;Residues: 1-427 <CHI>
 A;Cross references: EMBL:AF039043; PIDN:AB94196.1; GSPDB:GN00028; CESP:F39C12.3
 C;Experimental source: strain Bristol N2; Clone F39C12.3
 C;Genetics:
 A;Gene: CESP:F39C12.3
 A;Map position: X
 A;Introns: 42/3; 104/3; 133/3; 164/3; 213/3; 336/3
 Query Match 58.9%; Score 54; DB 2; Length 427;
 Best Local Similarity 69.2%; Pred. No. 16;
 Matches 9; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
 Qy 3 RPRPPYLPDRPRPP 15
 Db 338 RPRPPDPPDPPLP 350

RESULT 11
 S06175 Apidaecin Ib precursor - honeybee
 C;Species: Apis mellifera (honeybee)
 C;Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 16-Dec-1998
 C;Accession: S06175
 R;Casteels, P.; Ampe, C.; Jacobs, F.; Vaeck, M.; Tempst, P.
 BMBO J. 8, 2387-2391, 1989
 A;Title: Apidaecin: antibacterial peptides from honeybees.
 A;Reference number: S05383; MUID:90005446; PMID:2676519
 A;Accession: S06175
 A;Molecule type: protein
 A;Residues: 1-26 <PRO>
 F;1-8/Domain: propeptide #status experimental <MAT>
 Query Match 58.9%; Score 53; DB 2; Length 26;
 Best Local Similarity 72.7%; Pred. No. 1-3;
 Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 Qy 5 RPPYLPRPRPP 15
 Db 12 RPVYIPQPRPP 22

RESULT 12
 S35331 Apidaecin 22 precursor - honeybee
 C;Species: Apis mellifera (honeybee)
 C;Accession: S35331
 R;Casteels-Josson, K.; Capaci, T.; Casteels, P.; Tempst, P.
 BMBO J. 12, 1569-1578, 1993
 A;Title: Apidaecin multipeptide precursor structure: a putative mechanism for amplification
 A;Reference number: S35330; MUID:93223697; PMID:8467807
 A;Accession: S35331
 A;Status: preliminary
 A;Molecule type: DNA
 A;Residues: 1-144 <PRO>
 C;Superfamily: proyclic acidic repetitive protein
 A;Cross references: EMBL:X72576; PIDN:CAA51168.1; PMID:9297065

Query Match 58.9%; Score 53; DB 2; Length 144;
 Best Local Similarity 72.7%; Pred. No. 7.1;
 Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 5 RPPYLPRPRPP 15
 Db 102 RPVYIPQPRPP 112

RESULT 13
 T29373 hypothetical protein ZC404.1 - Caenorhabditis elegans
 C;Species: Caenorhabditis elegans
 C;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 09-Jun-2000

C;Accession: T29373
 R;Bentley, D.; Le, T.T.
 A;Description: The sequence of *C. elegans* cosmid 2C404.
 A;Status: preliminary; translated from GB/EMBL/DDJB
 A;Reference number: Z20614
 A;Molecule type: DNA
 A;Residues: 1-184 <PRO>
 A;Cross-references: EMBL:U55333; PIDN:AAA97987.1; GSPDB:GN00023; CESP:ZC404.1
 A;Experimental source: strain Bristol N2; clone ZC404
 C;Genetics:
 A;Gene: CESP:ZC404.1
 A;Map position: 5
 A;Introns: 15/2; 50/2; 75/2; 138/2
 C;Superfamily: Caenorhabditis elegans hypothetical protein 2C404.1
 Query Match 58.9%; Score 53; DB 2; Length 184;
 Best Local Similarity 90.0%; Pred. No. 9;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 3 RPRPPYLPDRPRPP 12
 Db 26 RPRKPYLPDRPRP 35

RESULT 14
 S35332 apidaecin 73 precursor - honeybee (fragment)
 C;Species: Apidaecin Ia
 C;Species: Apis mellifera (honeybee)
 C;Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 03-Nov-2000 -
 C;Accession: S35332; S05383
 R;Casteels-Josson, K.; Capaci, T.; Casteels, P.; Tempst, P.
 EMBO J. 12, 1569-1578, 1993
 A;Title: Apidaecin multipeptide precursor structure: a putative mechanism for amplification
 A;Reference number: S35330; MUID:93223697; PMID:8467807
 A;Accession: S35332
 A;Molecule type: mRNA
 A;Residues: 1-283 <PRO>
 A;Cross-references: EMBL:X72577; PIDN:9297066; PMID:9451169.1; PID:94539289
 A;Accession: S05383
 A;Molecule type: protein
 A;Residues: 258-283 <CA3>
 C;Superfamily: proline-rich protein
 F;266-283/Domain: proline-rich protein
 Query Match 58.9%; Score 53; DB 2; Length 283;
 Best Local Similarity 72.7%; Pred. No. 14;
 Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 Qy 5 RPPYLPRPRPP 15
 Db 241 RPVYIPQPRPP 251

RESULT 15
 E71415 probable coll wall Protein - *Arabidopsis thaliana*
 C;Species: *Arabidopsis thaliana* (mouse-ear cress)
 A;Variety: columbiensis
 C;Date: 03-Aug-1998 #sequence_revision 03-Aug-1998 #text_change 05-Dec-1998
 C;Accession: E71415
 R;Bevan, M.; Bancroft, I.; Bent, E.; Love, K.; Goodman, H.; Dean, C.; Bergkamp, R.; Dirks, P.; Wedder, H.; Wambutt, R.; Weitzman, T.M.; Terry, N.; Schaeffer, M.; Funk, B.; Avanash, T.; Hempel, S.; Kotter, P.; Entian, K.D.; Rieger, M.; Schaeffer, M.; Funk, B.; Nature 391, 485-488, 1998
 A;Authors: Mueller-Auer, S.; Silvey, M.; James, R.; Montfort, A.; Pons, A.; Puigdomenech, Ermohrt, A.; Moores, T.; Jones, J.D.G.; Eneva, T.; Palme, K.; Bensis, V.; Rechman, S.; Anschein, C.; Chalwatzi, N.
 A;Title: Analysis of 1.9 Mb of contiguous sequence from chromosome 4 of *Arabidopsis thaliana*
 A;Reference number: A71400; PMID:98121113; PMID:9461215
 A;Accession: E71415

A; Status: preliminary; nucleic acid sequence not shown; translation not shown
A; Molecule type: DNA
A; Residues: 1-428 <BEV>
A; Cross-references: GB:Z97338; NID:92244870; PID:e327461; PID:g224487#
C; Genetics:
A; Map position: 4COP9-4G3845

Query Match 58.9%; Score 53; DB 2; Length 428;
Best Local Similarity 61.5%; Pred. No. 21;
Matches 8; Conservative 2; Mismatches 3; Indels 0; Gaps 0;
Qy 3 RPRPPYLPRPRPP 15
:|||:|||:
Db 67 KPPPYYIFCPCPPP 79

Search completed: May 13, 2003, 10:41:48
Job time : 18 secs

THIS PAGE BLANK (uspto)

Scoring table:	BLOSUM62	Alignments
Gapop:	10.0	Gapext 0.5
Searched:	112892 seqs, 41476328 residues	RESULT 1
Total number of hits satisfying chosen parameters:	112892	PR39_PIG
Minimum DB seq length:	0	ID PR39_PIG STANDARD;
Maximum DB seq length:	2000000000	AC P80054; Q9TR84;
Post-processing:	Minimum Match 0%	DT 01-MAR-1992 (Rel. 21, Created)
	Maximum Match 100%	DT 01-OCT-1996 (Rel. 34, Last sequence update)
	Listing first 45 summaries	DT 16-OCT-2001 (Rel. 40, Last annotation update)
Database :	Swissprot_40:	DE Antibacterial protein PR-39 precursor.
		GN PR39.
		OS Sus scrofa (Pig).
		OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Butheria; Cetartiodactyla; Suina; Suidae; Sus.
		OX NCBI_TaxID:9823;
		RN [1]
		RN SEQUENCE FROM N.A.
		RX MEDLINE=95310216; PubMed=7624374;
		RA Gudmundsson G.H., Magnusson K.P., Chowdhary B.P., Johansson M., Andersson L., Boman H.G.;
		RT "Structure of the gene for porcine peptide antibiotic PR-39, a cathelin gene family member: comparative mapping of the locus for the human peptide antibiotic FALL-39."
		RT Proc. Natl. Acad. Sci. U.S.A. 92:7085-7089 (1995).
		RL [2]
		RN SEQUENCE FROM N.A.
		RC TISSUE-Bone marrow
		RX MEDLINE=94071853; PubMed=8250863;
		RA Sciori P., Zanetti M.;
		RT "A cDNA derived from pig bone marrow cells predicts a sequence identical to the intestinal antibacterial peptide PR-39."
		RT Biochem. Biophys. Res. Commun. 196:1058-1065 (1993).
		RN [3]
		RN SEQUENCE FROM N.A.
		RC TISSUE-Liver
		RX MEDLINE=96105365; PubMed=7498526;
		RA Zhao C., Ganz T., Lehrer R.I.;
		RT "Structures of genes for two cathelin-associated antimicrobial peptides: prophanin-2 and PR-39."
		RT FEBS Lett. 376:130-134 (1995).
		RN [4]
		RN SEQUENCE OF 131-169.
		RC TISSUE-Intestine
		RX MEDLINE=92111534; PubMed=1765098;
		RA Agerberth B., Lee J.-Y., Bergman T., Carlquist M., Boman H.G., Mutt V., Jernvall H.;
		RT "Amino acid sequence of PR-39. Isolation from pig intestine of a new member of the family of proline-arginine-rich antibacterial peptides."
		RT Eur. J. Biochem. 202:849-854 (1991).
		RL [5]
		RT SEQUENCE OF 131-164, AND FUNCTION.
		RC TISSUE-Neutrophils
		RX MEDLINE=95088504; PubMed=7996056;
		RA Shi J., Ross C.R., Chengappa M.M., Blecha F.;
		RT "Identification of a proline-arginine-rich antibacterial peptide from neutrophils that is analogous to PR-39, an antibacterial peptide from the small intestine."
		RT

RA	Scocchi M., Wang S., Zanetti M.; Submitted (DEC-1996) to the EMBL/GenBank/DBJ databases.
CC	-I - FUNCTION: EXERTS A POTENT ANTIMICROBIAL ACTIVITY AGAINST BOTH E.COLI AND B.MEGATERIUM.
CC	-I - TISSUE SPECIFICITY: SMALL INTESTINE AND BONE MARROW.
CC	-I - SIMILARITY: BELONGS TO THE CATHELICIDIN FAMILY.
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).
CC	DR EMBL; X87236; CAA60682_1; .
CC	DR EMBL; L23825; AAA1109_1; .
CC	DR EMBL; X89201; CAA61487_1; .
CC	DR PIR; S19563; S19563; .
CC	DR InterPro; IPR001894; Cathelicidin.
CC	DR PFAM; PF00666; Cathelicidins_1.
CC	DR PRODOM; P001838; Cathelicidin_1.
CC	DR PROSITE; PS00946; CATHELICIDINS_1; .
CC	DR PROSITE; PS00947; CATHELICIDINS_2; .
KW	ANTIBIOTIC; Amidation; Signal; .
FT	SIGNAL 1 29 POTENTIAL.
FT	PROPEP 30 130 ANTIBACTERIAL PROTEIN PR-39.
FT	CHAIN 131 169 PYRROLIDONE CARBOXYLIC ACID (BY SIMILARITY).
FT	MOD_RES 30 30 PYRROLIDONE CARBOXYLIC ACID (BY SIMILARITY).
FT	DISULFID 85 96 BY SIMILARITY.
FT	DISULFID 107 124 BY SIMILARITY.
FT	MOD_RES 169 169 AMIDATION (G-170 PROVIDE AMIDE GROUP).
FT	G -> A (IN REF. 2).
FT	CONFLICT 21 21 A -> T (IN REF. 1).
FT	CONFLICT 29 29 RQ -> QR (IN REF. 1).
FT	CONFLICT 90 91 IHS -> NDE (IN REF. 1).
FT	CONFLICT 117 119 P -> I (IN REF. 5).
FT	CONFLICT 157 157 P -> I (IN REF. 5).
SEQUENCE	19476 MW, 994B792798C0B133 CRC64;
SQ	SEQUENCE 172 AA; 19476 MW, 994B792798C0B133 CRC64;
Query Match	100.0%; Score 90; DB 1; Length 172;
Best Local Similarity	100.0%; Pred. No. 0 00022;
Matches	15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	1 RRRPRPPYLPRLPRPP 15
Db	131 RRRPRPPYLPRLPRPP 145
RESULT 2	
BTCT7_BOVIN	STANDARD;
AC	P19661;
ID	DT 01-FEB-1991 (Rel. 17, Created)
DT	DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT	DT 01-NOV-1997 (Rel. 35, Last annotation update)
DE	DE Bactenecin 7 precursor (BACT7) (PR-59).
GN	GN Bos taurus (Bovine)
OS	OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea; Bovidae; Bovinae; Bos.
OX	OX NCBI_TaxID=9913;
RP	RP SEQUENCE FROM N.A.
RC	RC TISSUE: Bone marrow;
RX	RX MEDLINE=9510107; PubMed=7925973;
RA	RA Scocchi M., Romeo D., Zanetti M.
RT	RT "Molecular cloning of Bac7, a proline- and arginine-rich antimicrobial peptide from bovine neutrophils.";
RT	RT FBS Lect. 352:197-200(1994).
RL	RL TISSUE=Liver;
RP	RP SEQUENCE FROM N.A.
RC	RC TISSUE=Liver;
RA	RA Scocchi M., Wang S., Zanetti M.; Submitted (DEC-1996) to the EMBL/GenBank/DBJ databases.
RN	RN [3]
RP	RP SEQUENCE OF 131-189.
RC	RC TISSUE=Neutrophils;
RX	RX MEDLINE=91035404; PubMed=2229048;
RA	RA Frank R.W., Gernaro R., Schneider K., Przybylski M., Romeo D.; "Amino acid sequences of two proline-rich bactenecins. Antimicrobial peptides of bovine neutrophils.";
RT	RT J. Biol. Chem. 265:18871-18874 (1990).
RN	RN [4]
RP	RP CHARACTERIZATION;
RX	RX CHAR000243; PubMed=8706679;
RA	RA Storici P., Tessi A., Lenarcic B., Romeo D.; "Purification and structural characterization of bovine cathelicidins, precursors of antimicrobial peptides.";
RT	RT Eur. J. Biochem. 238:769-776 (1996).
RL	RL -I - FUNCTION: EXPERTS, IN VITRO, A POTENT ANTIMICROBIAL ACTIVITY.
CC	CC PROBABLY DUE TO AN IMPAIRMENT OF THE FUNCTION OF THE RESPIRATORY CHAIN AND OF ENERGY-DEPENDENT ACTIVITIES IN THE INNER MEMBRANE OF SUSCEPTIBLE MICROORGANISMS.
CC	CC -I - TISSUE SPECIFICITY: LARGE GRANULES OF NEUTROPHILS.
CC	CC -I - PTM: ELASTASE IS RESPONSIBLE FOR ITS MATURATION.
CC	CC -I - MASS SPECTROMETRY: MW=18395; MW_ERR=1; METHOD=Electrospray; RANGE=0-100.
CC	CC -I - SIMILARITY: BELONGS TO THE CATHELICIDIN FAMILY.
CC	CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/ or send an email to license@isb-sib.ch).
CC	CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/ or send an email to license@isb-sib.ch).
EMBL	EMBL; L42977; AAA8759_1; .
DR	DR EMBL; Y09411; CAA70516_1; .
PIR	PIR; A36589; A16589;
DR	DR Pfam; PF00666; Cathelicidins_1.
DR	DR PRODOM; P000188; Cathelicidins_1.
DR	DR PROSITE; PS00946; CATHELICIDINS_1; .
DR	DR PROSITE; PS00947; CATHELICIDINS_2; .
DR	DR SIGNAL 1 29 POTENTIAL.
FT	FT CHAIN 131 190 BACTENECIN 7.
FT	FT PROPEP 189 190 PYRROLIDONE CARBOXYLIC ACID.
FT	FT MOD_RES 30 30 REMOVED PARTIALLY.
FT	FT DISUFD 85 96
FT	FT DISUFD 107 124
SQ	SQ SEQUENCE 190 AA; 191567 MW, 8CD07D7AA30A731C CRC64;
Query Match	Query Match 73.3%; Score 66; DB 1; Length 190;
Best Local Similarity	Best Local Similarity 85.7%; Pred. No. 0.15;
Matches	Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy	1 RRRPRPPYLPRLPRPP 14
Db	132 RIRPRPPRLPRPP 145
RESULT 3	
COTT_BACSU	COTT_BACSU STANDARD;
ID	ID COTT_BACSU
AC	AC P11853;
DT	DT 01-OCT-1989 (Rel. 12, Created)
DT	DT 01-OCT-1989 (Rel. 12, Last sequence update)
DT	DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE	DE spore coat protein T precursor.
GN	GN Bacillus subtilis.
OC	OC Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus.
OC	OC

RESULT 4							
OX NCBI_TaxID=1423;		BCT7_SHEEP	STANDARD;	PRT;	190 AA.		
RN [1]	SEQUENCE FROM N.A.		ID BCT7_SHEEP				
RC STRAIN=116 / JH642;		ID AC P50415;					
RX MEDLINE=89313296; PubMed=2546006;		DT 01-1996 (Rel. 34, Created)					
RA Aronson A.I., Song H.Y., Bourne N.;		DT 01-OCT-1996 (Rel. 34, Last sequence update)					
RT "Gene structure and precursor processing of a novel <i>Bacillus subtilis</i> spore coat protein.";		DT 01-NOV-1997 (Rel. 35, Last annotation update)					
RL Mol. Microbiol. 3:437-444 (1989).		DE Bactenecin 7 precursor (BAC7).					
RN [2]	SEQUENCE FROM N.A.		GN BAC7 .5.				
RC STRAIN=168;		OS Ovis aries (Sheep).					
RX MEDLINE=98044033; PubMed=9384377;		OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae; Bovidae; Caprinae; Ovis.					
RA Kunst F., Ogasawara N., Mozer I., Albertini A.M., Alloni G., Borsig L., Borsig R., Boursier L., Brans A., Braun M., Brignell S.C., Bron S., Brouillet V., Berrtero M.G., Bessieres P., Bolotin A., Borchert S., Bruschi C.V., Caldwell N.M., Carter N.M., Choi S.K., Codani J.J., Conneron I.F., Cummings N.J., Daniel R.A., Denizot F., Devine K.M., Dusserhoff A., Ehrlich S.D., Emmerson P.T., Entian K.D., Errington J., Fabre C., Ferrari B., Foulger D., Fritz C., Fujita M., Fujita Y., Fuma S., Galizzi A., Galleron N., Ghim S.Y., Glaser P., Goffeau A., Golightly E.J., Grandi G., Guiseppi G., Guy B.J., Haga K., Haiech J., Harwood C.R., Henaut A., Hilbert H., Hollsappel S., Hosono S., Hullo M.F., Itaya M., Jones L., Joris B., Karamata D., Kasaihara Y., Klaerr-Blanchard M., Klein C., Kobayashi Y., Koetter P., Konigstein G., Krogh S., Kumano M., Kurita K., Lapidus A., Lardinois S., Lauber J., Lazarevic V., Lee S.M., Levine A., Liu H., Masuda S., Maeli C., Medigue C., Medina R.P., Mellado R.P., Mizuno M., Moestl D., Nakai S., Noback M., Noone D., O'Reilly M., Ogawa K., Ogiwa A., Oudega B., Park S.H., Parro V., Pohl T.M., Portetelle D., Porwollik S., Prescott A.M., Presecan E., Pujic P., Purnelle B., Rapoport G., Rey M., Reynolds S., Rieger M., Rivolta C., Rocha E., Roche B., Rose M., Sadieh Y., Sato T., Scanlan E., Schlech S., Schroeter R., Scuffone F., Sekiguchi J., Sekowska A., Seror S.J., Serror P., Shin B.S., Soldo B., Sorokin A., Taccioni E., Takagi T., Tanaka T., Terpstra P., Togoni A., Takeuchi M., Tamakoshi A., Vandebroek M., Vannier A., Vian A., Wanbutt R., Wedler E., Weitzenerger T., Watanabe Y., Winters P., Wipat A., Yamamoto H., Yamane K., Yasumoto K., Yata K., Yoshida K., Yoshikawa H.F., Zumstein E., Yoshikawa H., Danchin A., RT "The complete genome sequence of the Gram-positive bacterium <i>Bacillus subtilis</i> ."; Nature 390:249-256 (1997).							
RC -!- FUNCTION: POSSIBLY PROTECTION OF SPORE AND PROBABLY PLAYS SOME ROLE IN GERMINATION.		CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).					
CC -!- SUBCELLULAR LOCATION: OUTER SURFACE OF ENDOSPORE.		CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).					
CC		CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).					
FT SIGNAL 1 44		FT SIGNAL 1 29					
FT CHAIN 45 107		FT PROPEP 30 130					
SQ SEQUENCE 107 AA; 12992 MW; AD1F6670C4CE29A3 CRC64;		FT CHAIN 131 190					
DR EMBL: Z99110; CAB13066.1; -;		FT MOD_RES 30 30					
DR PIR: S04835; S04835; -;		FT DISULFID 85 96					
DR Subtilist; Bg10495; cotT.		FT DISULFID 107 124					
KW Sporulation; Signal; Complete proteome.		SQ SEQUENCE 190 AA; 21829 MW; E4AAB1600B98371 CRC64;					
FT SIGNAL 1 44		Query Match 64.4%; Score 58; DB 1; Length 190;					
FT CHAIN 45 107		Best Local Similarity 78.6%; Pred. No. 1.2;					
SQ SEQUENCE 107 AA; 12992 MW; AD1F6670C4CE29A3 CRC64;		Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;					
DR EMBL: Z99110; CAB13066.1; -;		Qy 1 RRRRPPPYLPRPRP 14					
DR PIR: S04835; S04835; -;		Db 132 RLRLRPRPLRPRP 145					
RESULT 5							
OX NCBI_TaxID=1423;		AP14 APIME	STANDARD;	PRT;	168 AA.		
RN [1]	SEQUENCE FROM N.A.	ID AP14 APIME					
RC STRAIN=116 / JH642;		ID AC Q06601; P11525; P11527;					
RX MEDLINE=89313296; PubMed=2546006;		DT 01-OCT-1998 (Rel. 12, Created)					
RA Aronson A.I., Song H.Y., Bourne N.;		DT 01-JUN-1994 (Rel. 29, Last sequence update)					
RT "Gene structure and precursor processing of a novel <i>Bacillus subtilis</i> spore coat protein.";		DT 01-JUN-1994 (Rel. 29, Last annotation update)					
RL Mol. Microbiol. 3:437-444 (1989).		DE Apidaecin precursor, type 14.					
RN [2]	SEQUENCE FROM N.A.	GN AP14.					
RC STRAIN=168;		OS Apis mellifera (Honeybee).					
RX MEDLINE=98044033; PubMed=9384377;		OC Eukaryota; Metazoa; Arthropoda; Mandibulata; Pancrustacea; Hexapoda; Insecta; Pterygota; Neoptera; Endopterygota;					
RA Kunst F., Ogasawara N., Mozer I., Albertini A.M., Alloni G., Borsig L., Borsig R., Boursier L., Brans A., Braun M., Brignell S.C., Bron S., Brouillet V., Berrtero M.G., Bessieres P., Bolotin A., Borchert S., Bruschi C.V., Caldwell N.M., Carter N.M., Choi S.K., Codani J.J., Conneron I.F., Cummings N.J., Daniel R.A., Denizot F., Devine K.M., Dusserhoff A., Ehrlich S.D., Emmerson P.T., Entian K.D., Errington J., Fabre C., Ferrari B., Foulger D., Fritz C., Fujita M., Fujita Y., Fuma S., Galizzi A., Galleron N., Ghim S.Y., Glaser P., Goffeau A., Golightly E.J., Grandi G., Guiseppi G., Guy B.J., Haga K., Haiech J., Harwood C.R., Henaut A., Hilbert H., Hollsappel S., Hosono S., Hullo M.F., Itaya M., Jones L., Joris B., Karamata D., Kasaihara Y., Klaerr-Blanchard M., Klein C., Kobayashi Y., Koetter P., Konigstein G., Krogh S., Kumano M., Kurita K., Lapidus A., Lardinois S., Lauber J., Lazarevic V., Lee S.M., Levine A., Liu H., Masuda S., Maeli C., Medigue C., Medina R.P., Mellado R.P., Mizuno M., Moestl D., Nakai S., Noback M., Noone D., O'Reilly M., Ogawa K., Ogiwa A., Oudega B., Park S.H., Parro V., Pohl T.M., Portetelle D., Porwollik S., Prescott A.M., Presecan E., Pujic P., Purnelle B., Rapoport G., Rey M., Reynolds S., Rieger M., Rivolta C., Rocha E., Roche B., Rose M., Sadieh Y., Sato T., Scanlan E., Schlech S., Schroeter R., Scuffone F., Sekiguchi J., Sekowska A., Seror S.J., Serror P., Shin B.S., Soldo B., Sorokin A., Taccioni E., Takagi T., Tanaka T., Terpstra P., Togoni A., Takeuchi M., Tamakoshi A., Vandebroek M., Vannier A., Vian A., Wanbutt R., Wedler E., Weitzenerger T., Watanabe Y., Winters P., Wipat A., Yamamoto H., Yamane K., Yasumoto K., Yata K., Yoshida K., Yoshikawa H.F., Zumstein E., Yoshikawa H., Danchin A., RT "The complete genome sequence of the Gram-positive bacterium <i>Bacillus subtilis</i> ."; Nature 390:249-256 (1997).							
RC -!- FUNCTION: POSSIBLY PROTECTION OF SPORE AND PROBABLY PLAYS SOME ROLE IN GERMINATION.		CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).					
CC -!- SUBCELLULAR LOCATION: OUTER SURFACE OF ENDOSPORE.		CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).					
CC		CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).					
FT SIGNAL 1 44		FT SIGNAL 1 29					
FT CHAIN 45 107		FT PROPEP 30 130					
SQ SEQUENCE 107 AA; 12992 MW; AD1F6670C4CE29A3 CRC64;		FT CHAIN 131 190					
DR EMBL: Z99110; CAB13066.1; -;		FT MOD_RES 30 30					
DR PIR: S04835; S04835; -;		FT DISULFID 85 96					
DR Subtilist; Bg10495; cotT.		FT DISULFID 107 124					
KW Sporulation; Signal; Complete proteome.		SQ SEQUENCE 190 AA; 21829 MW; E4AAB1600B98371 CRC64;					
FT SIGNAL 1 44		Query Match 64.4%; Score 58; DB 1; Length 190;					
FT CHAIN 45 107		Best Local Similarity 78.6%; Pred. No. 1.2;					
SQ SEQUENCE 107 AA; 12992 MW; AD1F6670C4CE29A3 CRC64;		Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;					
DR EMBL: Z99110; CAB13066.1; -;		Qy 1 RRRRPPPYLPRPRP 14					
DR PIR: S04835; S04835; -;		Db 132 RLRLRPRPLRPRP 145					
RESULT 5							
OX NCBI_TaxID=1423;		AP14 APIME	STANDARD;	PRT;	168 AA.		
RN [1]	SEQUENCE FROM N.A.	ID AP14 APIME					
RC STRAIN=116 / JH642;		ID AC Q06601; P11525; P11527;					
RX MEDLINE=89313296; PubMed=2546006;		DT 01-OCT-1998 (Rel. 12, Created)					
RA Aronson A.I., Song H.Y., Bourne N.;		DT 01-JUN-1994 (Rel. 29, Last sequence update)					
RT "Gene structure and precursor processing of a novel <i>Bacillus subtilis</i> spore coat protein.";		DT 01-JUN-1994 (Rel. 29, Last annotation update)					
RL Mol. Microbiol. 3:437-444 (1989).		DE Apidaecin precursor, type 14.					
RN [2]	SEQUENCE FROM N.A.	GN AP14.					
RC STRAIN=168;		OS Apis mellifera (Honeybee).					
RX MEDLINE=98044033; PubMed=9384377;		OC Eukaryota; Metazoa; Arthropoda; Mandibulata; Pancrustacea; Hexapoda; Insecta; Pterygota; Neoptera; Endopterygota;					
RA Kunst F., Ogasawara N., Mozer I., Albertini A.M., Alloni G., Borsig L., Borsig R., Boursier L., Brans A., Braun M., Brignell S.C., Bron S., Brouillet V., Berrtero M.G., Bessieres P., Bolotin A., Borchert S., Bruschi C.V., Caldwell N.M., Carter N.M., Choi S.K., Codani J.J., Conneron I.F., Cummings N.J., Daniel R.A., Denizot F., Devine K.M., Dusserhoff A., Ehrlich S.D., Emmerson P.T., Entian K.D., Errington J., Fabre C., Ferrari B., Foulger D., Fritz C., Fujita M., Fujita Y., Fuma S., Galizzi A., Galleron N., Ghim S.Y., Glaser P., Goffeau A., Golightly E.J., Grandi G., Guiseppi G., Guy B.J., Haga K., Haiech J., Harwood C.R., Henaut A., Hilbert H., Hollsappel S., Hosono S., Hullo M.F., Itaya M., Jones L., Joris B., Karamata D., Kasaihara Y., Klaerr-Blanchard M., Klein C., Kobayashi Y., Koetter P., Konigstein G., Krogh S., Kumano M., Kurita K., Lapidus A., Lardinois S., Lauber J., Lazarevic V., Lee S.M., Levine A., Liu H., Masuda S., Maeli C., Medigue C., Medina R.P., Mellado R.P., Mizuno M., Moestl D., Nakai S., Noback M., Noone D., O'Reilly M., Ogawa K., Ogiwa A., Oudega B., Park S.H., Parro V., Pohl T.M., Portetelle D., Porwollik S., Prescott A.M., Presecan E., Pujic P., Purnelle B., Rapoport G., Rey M., Reynolds S., Rieger M., Rivolta C., Rocha E., Roche B., Rose M., Sadieh Y., Sato T., Scanlan E., Schlech S., Schroeter R., Scuffone F., Sekiguchi J., Sekowska A., Seror S.J., Serror P., Shin B.S., Soldo B., Sorokin A., Taccioni E., Takagi T., Tanaka T., Terpstra P., Togoni A., Takeuchi M., Tamakoshi A., Vandebroek M., Vannier A., Vian A., Wanbutt R., Wedler E., Weitzenerger T., Watanabe Y., Winters P., Wipat A., Yamamoto H., Yamane K., Yasumoto K., Yata K., Yoshida K., Yoshikawa H.F., Zumstein E., Yoshikawa H., Danchin A., RT "The complete genome sequence of the Gram-positive bacterium <i>Bacillus subtilis</i> ."; Nature 390:249-256 (1997).							
RC -!- FUNCTION: POSSIBLY PROTECTION OF SPORE AND PROBABLY PLAYS SOME ROLE IN GERMINATION.		CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).					
CC -!- SUBCELLULAR LOCATION: OUTER SURFACE OF ENDOSPORE.		CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).					
CC		CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).					
FT SIGNAL 1 44		FT SIGNAL 1 29					
FT CHAIN 45 107		FT PROPEP 30 130					
SQ SEQUENCE 107 AA; 12992 MW; AD1F6670C4CE29A3 CRC64;		FT CHAIN 131 190					
DR EMBL: Z99110; CAB13066.1; -;		FT MOD_RES 30 30					
DR PIR: S04835; S04835; -;		FT DISULFID 85 96					
DR Subtilist; Bg10495; cotT.		FT DISULFID 107 124					
KW Sporulation; Signal; Complete proteome.		SQ SEQUENCE 190 AA; 21829 MW; E4AAB1600B98371 CRC64;					
FT SIGNAL 1 44		Query Match 64.4%; Score 58; DB 1; Length 190;					
FT CHAIN 45 107		Best Local Similarity 78.6%; Pred. No. 1.2;					
SQ SEQUENCE 107 AA; 12992 MW; AD1F6670C4CE29A3 CRC64;		Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;					
DR EMBL: Z99110; CAB13066.1; -;		Qy 1 RRRRPPPYLPRPRP 14					
DR PIR: S04835; S04835; -;		Db 132 RLRLRPRPLRPRP 145					

OC	Aculeata; Apoidea; Apidae; Apis.	RP	SEQUENCE FROM N.A.
OX	NCBI_TaxID:7460;	RA	Dolan A.;
RN	[1] _SEQUENCE FROM N.A. PubMed=8467807;	RI	Submitted (FEB-1997) to the EMBL/GenBank/DBJ databases.
RX	MEDLINE=332223697; PubMed=8467807;	CC	-I- FUNCTION: BINDS DNA AND RNA (BY SIMILARITY).
RA	Casteels-Josson K., Capaci T., Casteels P., Tempst P.;	CC	-I- SUBCELLULAR LOCATION: Nuclear; nucleolar (By similarity).
RT	"Apidaecin multipептид precursor structure: a putative mechanism for amplification of the insect antibacterial response.";	CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation -
RL	EMBO J. 12:1569-1578 (1993).	CC	the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).
RN	[2]	CC	
RT	SEQUENCE OF APIDAECINS IA/IB/II.	CC	
RX	DR	DRML; 286099; CAB06719.1;	
RC	DR	KW	DNA-binding; RNA-binding; Repeat; Nuclear protein.
RX	DR	FT	DOMAIN 90 146 11 X 6 AA TANDEM REPEATS.
RA	FT	FT	REPEAT 90 95 1.
RT	FT	FT	REPEAT 96 101 2.
RL	FT	FT	REPEAT 102 104 3.
CC	FT	FT	REPEAT 105 110 4.
CC	FT	FT	REPEAT 111 116 5.
CC	FT	FT	REPEAT 117 122 6.
CC	FT	FT	REPEAT 123 128 7.
CC	FT	FT	REPEAT 129 130 8.
CC	FT	FT	REPEAT 131 134 9.
CC	FT	FT	REPEAT 135 140 10.
CC	FT	FT	REPEAT 141 146 11.
CC	SEQUENCE	151 AA;	16297 MW; FAB751F23C3DB6AE CRC64;
DR	PIR; S03383; CAA51167.1; -.	Query Match	61.7% Score 55.5; DB 1; Length 151;
DR	PIR; S03383; S06675; S06675.	Best Local Similarity	73.3%; Pred. No. 1.9;
DR	PIR; S06675; S06675.	Matches	11; Conservative 1; Mismatches 2; Indels 1; Gaps 1;
DR	PIR; S31330; S35330.	Qy	2 RRPYPPVPLPR-PRPP 15
DR	InterPro; IPR04838; Apidaecin.	Db	127 RPPRPPRVRPRBPRPP 141
DR	PFAM; PF00807; Apidaecin_5.	RESULT 7	
DR	Insect immunity; Antibiotic; Hemolymph; Signal; Multigene family;	ID	AP22_APIME STANDARD; PRT; 144 AA.
DR	Clavage on pair of basic residues; Repeat.	AC	P35581; P11525; P11526;
DR	SIGNAL 1 19 POTENTIAL.	DT	01-OCT-1989 (Rel. 12, Created)
FT	PROPEP 35 42	DT	01-JUN-1994 (Rel. 29, Last sequence update)
FT	PEPTIDE 43 60	DE	Apidaecin precursor, type 22.
FT	PROPEP 63 70	OS	Apis mellifera (Honeybee).
FT	PEPTIDE 71 88	OC	Eukaryota; Metazoa; Arthropoda; Mandibulata; Pancrustacea; Hexapoda; Insecta; Pterygota; Neoptera; Endopterygota; Hymenoptera; Apocrita; Aculeata; Apoidea; Apidae; Apis.
FT	PROPEP 91 98	OC	
FT	PEPTIDE 99 116	RL	NCBI_TaxID=7460;
FT	PROPEP 119 124	RN	SEQUENCE FROM N.A.
FT	PEPTIDE 125 142	RX	MEDLINE=93223697; PubMed=8467807;
FT	PROPEP 145 150	RA	Casteels P., Ampe C., Jacobs F., Vaeck M., Tempst P.;
FT	PEPTIDE 151 168	RT	"Apidaecin multipептид precursor structure: a putative mechanism for amplification of the insect antibacterial response.";
SEQUENCE	168 AA;	RL	EMBO J. 12:1569-1578 (1993).
SEQUENCE	19180 MW;	RN	
SEQUENCE	594B931254C04A37 CRC64;	RN	SEQUENCE (APIDAECINS IA/IB).
DR	Query Match	62.8% Score 56.5; DB 1; Length 168;	
DR	Best Local Similarity	Pred. No. 1.6; 2; Mismatches 2; Indels 7; Gaps 1;	
DR	Matches	11; Conservative 1; Mismatches 2; Indels 7; Gaps 1;	
DR	Qy	1 RRP-----RPPYPLPRRPP 15	
DR	Db	117 RPPRPPRVRPRBPRPP 138	
RESULT 6			
RNB_HSV2H	STANDARD;	PRT;	151 AA.
ID	RNB_HSV2H	AC	P87479;
AC	P87479;	DT	16-OCT-2001 (Rel. 40, Created)
AC	P87479;	DT	16-OCT-2001 (Rel. 40, Last sequence update)
AC	P87479;	DT	15-JUN-2002 (Rel. 41, Last annotation update)
AC	P87479;	DE	Potential RNA-binding protein.
AC	P87479;	GN	US1.
AC	P87479;	OS	Herpes simplex virus (type 2 / strain HG52).
AC	P87479;	OC	Viruses dsDNA viruses, no RNA stage; Herpesviridae;
AC	P87479;	OC	Alphaherpesvirinae; Simplexvirus.
AC	P87479;	OX	NCBI_TaxID=10315;
AC	P87479;	OX	

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

[1]

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

[2]

use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.iab-sib.ch/announce/> or send an email to license@iab-sib.ch)

CC	-	perlecan and triple helical collagens type I and type II.
CC	-	SUBCELLULAR LOCATION: Extracellular matrix.
CC	-	DOMAIN: The basic amino-terminal Arg-Pro-rich birds heparin and heparan sulfate. Binds collagens type I and type II through its leucine-rich repeat domain.
CC	-	SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCANS (SLRPs) FAMILY. CLASS II SUBFAMILY.
CC	-	SIMILARITY: CONTAINS 12 LEUCINE-RICH REPEATS (LRR).
CC	-	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement. (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).
CC	-	EMBL; AF16568; AAC2323; 1; -.
DR	DR	InterPro; IPR01611; LRR.
DR	DR	InterPro; IPR00372; LRR_Nterm.
DR	DR	InterPro; IPR003592; LRR_out.
DR	DR	InterPro; IPR03591; LRR_typ.
PFAM	DR	PF00560; LRR; 10.
PFAM	DR	PF00560; LRR; 10.
PRINTS	DR	PR00019; LEURCHRPT.
SMART	DR	SM00370; LRR; 7.
SMART	DR	SM00013; LRRN; 1.
SMART	DR	SM00369; LRR_TYP; 7.
KW	GW	Glycoprotein; Extracellular matrix; Repeat; Leucine-rich repeat;
KW	GW	Signal.
FT	FT	SIGNAL. 1 21 POTENTIAL.
FT	FT	CHAIN 22 381 PROLARGIN.
FT	FT	DOMAIN 72 88 CYS-RICH.
FT	FT	REPEAT 94 113 LRR-S 1.
FT	FT	REPEAT 114 137 LRR-T 1.
FT	FT	REPEAT 138 161 LRR-T 2.
FT	FT	REPEAT 162 182 LRR-S 2.
FT	FT	REPEAT 183 206 LRR-T 3.
FT	FT	REPEAT 207 232 LRR-T 4.
FT	FT	REPEAT 233 253 LRR-S 3.
FT	FT	REPEAT 254 277 LRR-T 5.
FT	FT	REPEAT 278 302 LRR-T 6.
FT	FT	REPEAT 303 322 LRR-S 4.
FT	FT	REPEAT 323 361 LRR-T 7.
FT	FT	REPEAT 362 381 LRR-T 8.
FT	FT	DOMAIN 196 201 POLY-LBU.
FT	FT	DISUFTD 331 372 BY SIMILARITY.
CARBODY	FT	CARBODY 123 123 N-LINKEED (GLCNAC. . .) (POTENTIAL).
CARBODY	FT	CARBODY 288 288 N-LINKEED (GLCNAC. . .) (POTENTIAL).
CARBODY	FT	CARBODY 319 319 N-LINKEED (GLCNAC. . .) (POTENTIAL).
CARBODY	FT	CARBODY 326 326 N-LINKEED (GLCNAC. . .) (POTENTIAL).
SEQUENCE	SQ	SEQUENCE 381 AA; 43682 MW; 23D999C01BB772A0 CRC64;
Query	Best Local Similarity	58.0%; Score 53; DB 1; Length 381;
Matches	10; Conservative	76.9%; Pred. No. 9.2%; Mismatches 0; Indels 0; Gaps 0; PRT; 261 AA.
Qy	2 RRRPPYPLPRPRP 14	
Db	25 RRRPRPRPRP 37	
RESULT 10		
RL1	RL1_HSV2H	
ID	RL1_HSV2H	STANDARD;
AC	P28283;	PRT;
DT	01-DEC-1992 (Rel. 24, Created)	
DT	01-DEC-1992 (Rel. 24, Last sequence update)	
DT	01-NOV-1997 (Rel. 35, Last annotation update)	
DE	Neurovirovirus factor (ICP34.5).	
GN	RL1.	
OS	Herpes simplex virus (type 2 / strain HG52).	
OS	Viruses; dsDNA viruses; no RNA state; Herpesviridae;	

DR PROSITE; PS50055; TYR_PHOSPHATASE_PTP; 1.
DR PROSITE; PS50056; TYR_PHOSPHATASE_2; 1.
KW Structural protein; Cytoskeleton; Hydrolase.
FT DOMAIN 75 239 BAND 4.1-LIKE.
FT DOMAIN 935 1189 PROTEIN-TYROSINE PHOSPHATASE.
FT ACT SITE 1123 1123 BY SIMILARITY.
FT DOMAIN 566 573 POLY-PRO.
FT DOMAIN 635 639 POLY-GLY.
FT DOMAIN 712 718 POLY-GLU.
SQ SEQUENCE 1189 AA; 135030 MW; 2B85BESF9C723303 CRC64;
Query Match 57.2%; Score 51.5; DB 1; Length 1189;
Best Local Similarity 83.3%; Pred. No. 42;
Matches 10; Conservative 0; Mismatches 1; Indels 1; Gaps 1;
Qy 3 RPRPPVLPVRPPR 14
Db 565 RPPPPY-PRPRP 575

Search completed: May 13, 2003, 10:40:51
Job time : 13 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.4 p5_4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw mode.

Run on: May 13, 2003, 10:37:02 ; Search time 29 Seconds
(without alignments)
106.576 Million cell updates/sec

Title: US-09-426-011D-3
Perfect score: 90
Sequence: 1_RRRPPPPYLPRPRPP 15

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 671580 seqs, 206047115 residues

Total number of hits satisfying chosen parameters: 671580

Minimum DB seq length: 0

Maximum DB seq length: 20000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SPTREMBL 21:
1: sp_archaea:
2: sp_bacteria:
3: sp_fungi:
4: sp_human:
5: sp_invertebrate:
6: sp_mammal:
7: sp_mhc:
8: sp_organelle:
9: sp_phage:
10: sp_plant:
11: sp_rabbit:
12: sp_virus:
13: sp_vertebrate:
14: sp_unclassified:
15: sp_rvirus:
16: sp_bacteria:
17: sp_archaea:
18: sp_bacteria:
19: sp_fungi:
20: sp_invertebrate:
21: sp_mammal:
22: sp_mhc:
23: sp_organelle:
24: sp_phage:
25: sp_plant:
26: sp_rabbit:
27: sp_virus:
28: sp_vertebrate:
29: sp_unclassified:
30: sp_rvirus:
31: sp_bacteria:
32: sp_fungi:
33: sp_invertebrate:
34: sp_mammal:
35: sp_mhc:
36: sp_organelle:
37: sp_phage:
38: sp_plant:
39: sp_rabbit:
40: sp_virus:
41: sp_vertebrate:
42: sp_unclassified:
43: sp_rvirus:
44: sp_bacteria:
45: sp_fungi:
46: sp_invertebrate:
47: sp_mammal:
48: sp_mhc:
49: sp_organelle:
50: sp_phage:
51: sp_plant:
52: sp_rabbit:
53: sp_virus:
54: sp_vertebrate:
55: sp_unclassified:
56: sp_rvirus:
57: sp_bacteria:
58: sp_fungi:
59: sp_invertebrate:
60: sp_mammal:
61: sp_mhc:
62: sp_organelle:
63: sp_phage:
64: sp_plant:
65: sp_rabbit:
66: sp_virus:
67: sp_vertebrate:
68: sp_unclassified:
69: sp_rvirus:
70: sp_bacteria:
71: sp_fungi:
72: sp_invertebrate:
73: sp_mammal:
74: sp_mhc:
75: sp_organelle:
76: sp_phage:
77: sp_plant:
78: sp_rabbit:
79: sp_virus:
80: sp_vertebrate:
81: sp_unclassified:
82: sp_rvirus:
83: sp_bacteria:
84: sp_fungi:
85: sp_invertebrate:
86: sp_mammal:
87: sp_mhc:
88: sp_organelle:
89: sp_phage:
90: sp_plant:
91: sp_rabbit:
92: sp_virus:
93: sp_vertebrate:
94: sp_unclassified:
95: sp_rvirus:
96: sp_bacteria:
97: sp_fungi:
98: sp_invertebrate:
99: sp_mammal:
100: sp_mhc:
101: sp_organelle:
102: sp_phage:
103: sp_plant:
104: sp_rabbit:
105: sp_virus:
106: sp_vertebrate:
107: sp_unclassified:
108: sp_rvirus:
109: sp_bacteria:
110: sp_fungi:
111: sp_invertebrate:
112: sp_mammal:
113: sp_mhc:
114: sp_organelle:
115: sp_phage:
116: sp_plant:
117: sp_rabbit:
118: sp_virus:
119: sp_vertebrate:
120: sp_unclassified:
121: sp_rvirus:
122: sp_bacteria:
123: sp_fungi:
124: sp_invertebrate:
125: sp_mammal:
126: sp_mhc:
127: sp_organelle:
128: sp_phage:
129: sp_plant:
130: sp_rabbit:
131: sp_virus:
132: sp_vertebrate:
133: sp_unclassified:
134: sp_rvirus:
135: sp_bacteria:
136: sp_fungi:
137: sp_invertebrate:
138: sp_mammal:
139: sp_mhc:
140: sp_organelle:
141: sp_phage:
142: sp_plant:
143: sp_rabbit:
144: sp_virus:
145: sp_vertebrate:
146: sp_unclassified:
147: sp_rvirus:
148: sp_bacteria:
149: sp_fungi:
150: sp_invertebrate:
151: sp_mammal:
152: sp_mhc:
153: sp_organelle:
154: sp_phage:
155: sp_plant:
156: sp_rabbit:
157: sp_virus:
158: sp_vertebrate:
159: sp_unclassified:
160: sp_rvirus:
161: sp_bacteria:
162: sp_fungi:
163: sp_invertebrate:
164: sp_mammal:
165: sp_mhc:
166: sp_organelle:
167: sp_phage:
168: sp_plant:
169: sp_rabbit:
170: sp_virus:
171: sp_vertebrate:
172: sp_unclassified:
173: sp_rvirus:
174: sp_bacteria:
175: sp_fungi:
176: sp_invertebrate:
177: sp_mammal:
178: sp_mhc:
179: sp_organelle:
180: sp_phage:
181: sp_plant:
182: sp_rabbit:
183: sp_virus:
184: sp_vertebrate:
185: sp_unclassified:
186: sp_rvirus:
187: sp_bacteria:
188: sp_fungi:
189: sp_invertebrate:
190: sp_mammal:
191: sp_mhc:
192: sp_organelle:
193: sp_phage:
194: sp_plant:
195: sp_rabbit:
196: sp_virus:
197: sp_vertebrate:
198: sp_unclassified:
199: sp_rvirus:
200: sp_bacteria:
201: sp_fungi:
202: sp_invertebrate:
203: sp_mammal:
204: sp_mhc:
205: sp_organelle:
206: sp_phage:
207: sp_plant:
208: sp_rabbit:
209: sp_virus:
210: sp_vertebrate:
211: sp_unclassified:
212: sp_rvirus:
213: sp_bacteria:
214: sp_fungi:
215: sp_invertebrate:
216: sp_mammal:
217: sp_mhc:
218: sp_organelle:
219: sp_phage:
220: sp_plant:
221: sp_rabbit:
222: sp_virus:
223: sp_vertebrate:
224: sp_unclassified:
225: sp_rvirus:
226: sp_bacteria:
227: sp_fungi:
228: sp_invertebrate:
229: sp_mammal:
230: sp_mhc:
231: sp_organelle:
232: sp_phage:
233: sp_plant:
234: sp_rabbit:
235: sp_virus:
236: sp_vertebrate:
237: sp_unclassified:
238: sp_rvirus:
239: sp_bacteria:
240: sp_fungi:
241: sp_invertebrate:
242: sp_mammal:
243: sp_mhc:
244: sp_organelle:
245: sp_phage:
246: sp_plant:
247: sp_rabbit:
248: sp_virus:
249: sp_vertebrate:
250: sp_unclassified:
251: sp_rvirus:
252: sp_bacteria:
253: sp_fungi:
254: sp_invertebrate:
255: sp_mammal:
256: sp_mhc:
257: sp_organelle:
258: sp_phage:
259: sp_plant:
260: sp_rabbit:
261: sp_virus:
262: sp_vertebrate:
263: sp_unclassified:
264: sp_rvirus:
265: sp_bacteria:
266: sp_fungi:
267: sp_invertebrate:
268: sp_mammal:
269: sp_mhc:
270: sp_organelle:
271: sp_phage:
272: sp_plant:
273: sp_rabbit:
274: sp_virus:
275: sp_vertebrate:
276: sp_unclassified:
277: sp_rvirus:
278: sp_bacteria:
279: sp_fungi:
280: sp_invertebrate:
281: sp_mammal:
282: sp_mhc:
283: sp_organelle:
284: sp_phage:
285: sp_plant:
286: sp_rabbit:
287: sp_virus:
288: sp_vertebrate:
289: sp_unclassified:
290: sp_rvirus:
291: sp_bacteria:
292: sp_fungi:
293: sp_invertebrate:
294: sp_mammal:
295: sp_mhc:
296: sp_organelle:
297: sp_phage:
298: sp_plant:
299: sp_rabbit:
300: sp_virus:
301: sp_vertebrate:
302: sp_unclassified:
303: sp_rvirus:
304: sp_bacteria:
305: sp_fungi:
306: sp_invertebrate:
307: sp_mammal:
308: sp_mhc:
309: sp_organelle:
310: sp_phage:
311: sp_plant:
312: sp_rabbit:
313: sp_virus:
314: sp_vertebrate:
315: sp_unclassified:
316: sp_rvirus:
317: sp_bacteria:
318: sp_fungi:
319: sp_invertebrate:
320: sp_mammal:
321: sp_mhc:
322: sp_organelle:
323: sp_phage:
324: sp_plant:
325: sp_rabbit:
326: sp_virus:
327: sp_vertebrate:
328: sp_unclassified:
329: sp_rvirus:
330: sp_bacteria:
331: sp_fungi:
332: sp_invertebrate:
333: sp_mammal:
334: sp_mhc:
335: sp_organelle:
336: sp_phage:
337: sp_plant:
338: sp_rabbit:
339: sp_virus:
340: sp_vertebrate:
341: sp_unclassified:
342: sp_rvirus:
343: sp_bacteria:
344: sp_fungi:
345: sp_invertebrate:
346: sp_mammal:
347: sp_mhc:
348: sp_organelle:
349: sp_phage:
350: sp_plant:
351: sp_rabbit:
352: sp_virus:
353: sp_vertebrate:
354: sp_unclassified:
355: sp_rvirus:
356: sp_bacteria:
357: sp_fungi:
358: sp_invertebrate:
359: sp_mammal:
360: sp_mhc:
361: sp_organelle:
362: sp_phage:
363: sp_plant:
364: sp_rabbit:
365: sp_virus:
366: sp_vertebrate:
367: sp_unclassified:
368: sp_rvirus:
369: sp_bacteria:
370: sp_fungi:
371: sp_invertebrate:
372: sp_mammal:
373: sp_mhc:
374: sp_organelle:
375: sp_phage:
376: sp_plant:
377: sp_rabbit:
378: sp_virus:
379: sp_vertebrate:
380: sp_unclassified:
381: sp_rvirus:
382: sp_bacteria:
383: sp_fungi:
384: sp_invertebrate:
385: sp_mammal:
386: sp_mhc:
387: sp_organelle:
388: sp_phage:
389: sp_plant:
390: sp_rabbit:
391: sp_virus:
392: sp_vertebrate:
393: sp_unclassified:
394: sp_rvirus:
395: sp_bacteria:
396: sp_fungi:
397: sp_invertebrate:
398: sp_mammal:
399: sp_mhc:
400: sp_organelle:
401: sp_phage:
402: sp_plant:
403: sp_rabbit:
404: sp_virus:
405: sp_vertebrate:
406: sp_unclassified:
407: sp_rvirus:
408: sp_bacteria:
409: sp_fungi:
410: sp_invertebrate:
411: sp_mammal:
412: sp_mhc:
413: sp_organelle:
414: sp_phage:
415: sp_plant:
416: sp_rabbit:
417: sp_virus:
418: sp_vertebrate:
419: sp_unclassified:
420: sp_rvirus:
421: sp_bacteria:
422: sp_fungi:
423: sp_invertebrate:
424: sp_mammal:
425: sp_mhc:
426: sp_organelle:
427: sp_phage:
428: sp_plant:
429: sp_rabbit:
430: sp_virus:
431: sp_vertebrate:
432: sp_unclassified:
433: sp_rvirus:
434: sp_bacteria:
435: sp_fungi:
436: sp_invertebrate:
437: sp_mammal:
438: sp_mhc:
439: sp_organelle:
440: sp_phage:
441: sp_plant:
442: sp_rabbit:
443: sp_virus:
444: sp_vertebrate:
445: sp_unclassified:
446: sp_rvirus:
447: sp_bacteria:
448: sp_fungi:
449: sp_invertebrate:
450: sp_mammal:
451: sp_mhc:
452: sp_organelle:
453: sp_phage:
454: sp_plant:
455: sp_rabbit:
456: sp_virus:
457: sp_vertebrate:
458: sp_unclassified:
459: sp_rvirus:
460: sp_bacteria:
461: sp_fungi:
462: sp_invertebrate:
463: sp_mammal:
464: sp_mhc:
465: sp_organelle:
466: sp_phage:
467: sp_plant:
468: sp_rabbit:
469: sp_virus:
470: sp_vertebrate:
471: sp_unclassified:
472: sp_rvirus:
473: sp_bacteria:
474: sp_fungi:
475: sp_invertebrate:
476: sp_mammal:
477: sp_mhc:
478: sp_organelle:
479: sp_phage:
480: sp_plant:
481: sp_rabbit:
482: sp_virus:
483: sp_vertebrate:
484: sp_unclassified:
485: sp_rvirus:
486: sp_bacteria:
487: sp_fungi:
488: sp_invertebrate:
489: sp_mammal:
490: sp_mhc:
491: sp_organelle:
492: sp_phage:
493: sp_plant:
494: sp_rabbit:
495: sp_virus:
496: sp_vertebrate:
497: sp_unclassified:
498: sp_rvirus:
499: sp_bacteria:
500: sp_fungi:
501: sp_invertebrate:
502: sp_mammal:
503: sp_mhc:
504: sp_organelle:
505: sp_phage:
506: sp_plant:
507: sp_rabbit:
508: sp_virus:
509: sp_vertebrate:
510: sp_unclassified:
511: sp_rvirus:
512: sp_bacteria:
513: sp_fungi:
514: sp_invertebrate:
515: sp_mammal:
516: sp_mhc:
517: sp_organelle:
518: sp_phage:
519: sp_plant:
520: sp_rabbit:
521: sp_virus:
522: sp_vertebrate:
523: sp_unclassified:
524: sp_rvirus:
525: sp_bacteria:
526: sp_fungi:
527: sp_invertebrate:
528: sp_mammal:
529: sp_mhc:
530: sp_organelle:
531: sp_phage:
532: sp_plant:
533: sp_rabbit:
534: sp_virus:
535: sp_vertebrate:
536: sp_unclassified:
537: sp_rvirus:
538: sp_bacteria:
539: sp_fungi:
540: sp_invertebrate:
541: sp_mammal:
542: sp_mhc:
543: sp_organelle:
544: sp_phage:
545: sp_plant:
546: sp_rabbit:
547: sp_virus:
548: sp_vertebrate:
549: sp_unclassified:
550: sp_rvirus:
551: sp_bacteria:
552: sp_fungi:
553: sp_invertebrate:
554: sp_mammal:
555: sp_mhc:
556: sp_organelle:
557: sp_phage:
558: sp_plant:
559: sp_rabbit:
560: sp_virus:
561: sp_vertebrate:
562: sp_unclassified:
563: sp_rvirus:
564: sp_bacteria:
565: sp_fungi:
566: sp_invertebrate:
567: sp_mammal:
568: sp_mhc:
569: sp_organelle:
570: sp_phage:
571: sp_plant:
572: sp_rabbit:
573: sp_virus:
574: sp_vertebrate:
575: sp_unclassified:
576: sp_rvirus:
577: sp_bacteria:
578: sp_fungi:
579: sp_invertebrate:
580: sp_mammal:
581: sp_mhc:
582: sp_organelle:
583: sp_phage:
584: sp_plant:
585: sp_rabbit:
586: sp_virus:
587: sp_vertebrate:
588: sp_unclassified:
589: sp_rvirus:
590: sp_bacteria:
591: sp_fungi:
592: sp_invertebrate:
593: sp_mammal:
594: sp_mhc:
595: sp_organelle:
596: sp_phage:
597: sp_plant:
598: sp_rabbit:
599: sp_virus:
600: sp_vertebrate:
601: sp_unclassified:
602: sp_rvirus:
603: sp_bacteria:
604: sp_fungi:
605: sp_invertebrate:
606: sp_mammal:
607: sp_mhc:
608: sp_organelle:
609: sp_phage:
610: sp_plant:
611: sp_rabbit:
612: sp_virus:
613: sp_vertebrate:
614: sp_unclassified:
615: sp_rvirus:
616: sp_bacteria:
617: sp_fungi:
618: sp_invertebrate:
619: sp_mammal:
620: sp_mhc:
621: sp_organelle:
622: sp_phage:
623: sp_plant:
624: sp_rabbit:
625: sp_virus:
626: sp_vertebrate:
627: sp_unclassified:
628: sp_rvirus:
629: sp_bacteria:
630: sp_fungi:
631: sp_invertebrate:
632: sp_mammal:
633: sp_mhc:
634: sp_organelle:
635: sp_phage:
636: sp_plant:
637: sp_rabbit:
638: sp_virus:
639: sp_vertebrate:
640: sp_unclassified:
641: sp_rvirus:
642: sp_bacteria:
643: sp_fungi:
644: sp_invertebrate:
645: sp_mammal:
646: sp_mhc:
647: sp_organelle:
648: sp_phage:
649: sp_plant:
650: sp_rabbit:
651: sp_virus:
652: sp_vertebrate:
653: sp_unclassified:
654: sp_rvirus:
655: sp_bacteria:
656: sp_fungi:
657: sp_invertebrate:
658: sp_mammal:
659: sp_mhc:
660: sp_organelle:
661: sp_phage:
662: sp_plant:
663: sp_rabbit:
664: sp_virus:
665: sp_vertebrate:
666: sp_unclassified:
667: sp_rvirus:
668: sp_bacteria:
669: sp_fungi:
670: sp_invertebrate:
671: sp_mammal:
672: sp_mhc:
673: sp_organelle:
674: sp_phage:
675: sp_plant:
676: sp_rabbit:
677: sp_virus:
678: sp_vertebrate:
679: sp_unclassified:
680: sp_rvirus:
681: sp_bacteria:
682: sp_fungi:
683: sp_invertebrate:
684: sp_mammal:
685: sp_mhc:
686: sp_organelle:
687: sp_phage:
688: sp_plant:
689: sp_rabbit:
690: sp_virus:
691: sp_vertebrate:
692: sp_unclassified:
693: sp_rvirus:
694: sp_bacteria:
695: sp_fungi:
696: sp_invertebrate:
697: sp_mammal:
698: sp_mhc:
699: sp_organelle:
700: sp_phage:
701: sp_plant:
702: sp_rabbit:
703: sp_virus:
704: sp_vertebrate:
705: sp_unclassified:
706: sp_rvirus:
707: sp_bacteria:
708: sp_fungi:
709: sp_invertebrate:
710: sp_mammal:
711: sp_mhc:
712: sp_organelle:
713: sp_phage:
714: sp_plant:
715: sp_rabbit:
716: sp_virus:
717: sp_vertebrate:
718: sp_unclassified:
719: sp_rvirus:
720: sp_bacteria:
721: sp_fungi:
722: sp_invertebrate:
723: sp_mammal:
724: sp_mhc:
725: sp_organelle:
726: sp_phage:
727: sp_plant:
728: sp_rabbit:
729: sp_virus:
730: sp_vertebrate:
731: sp_unclassified:
732: sp_rvirus:
733: sp_bacteria:
734: sp_fungi:
735: sp_invertebrate:
736: sp_mammal:
737: sp_mhc:
738: sp_organelle:
739: sp_phage:
740: sp_plant:
741: sp_rabbit:
742: sp_virus:
743: sp_vertebrate:
744: sp_unclassified:
745: sp_rvirus:
746: sp_bacteria:
747: sp_fungi:
748: sp_invertebrate:
749: sp_mammal:
750: sp_mhc:
751: sp_organelle:
752: sp_phage:
753: sp_plant:
754: sp_rabbit:
755: sp_virus:
756: sp_vertebrate:
757: sp_unclassified:
758: sp_rvirus:
759: sp_bacteria:
760: sp_fungi:
761: sp_invertebrate:
762: sp_mammal:
763: sp_mhc:
764: sp_organelle:
765: sp_phage:
766: sp_plant:
767: sp_rabbit:
768: sp_virus:
769: sp_vertebrate:
770: sp_unclassified:
771: sp_rvirus:
772: sp_bacteria:
773: sp_fungi:
774: sp_invertebrate:
775: sp_mammal:
776: sp_mhc:
777: sp_organelle:
778: sp_phage:
779: sp_plant:
780: sp_rabbit:
781: sp_virus:
782: sp_vertebrate:
783: sp_unclassified:
784: sp_rvirus:
785: sp_bacteria:
786: sp_fungi:
787: sp_invertebrate:
788: sp_mammal:
789: sp_mhc:
790: sp_organelle:
791: sp_phage:
792: sp_plant:
793: sp_rabbit:
794: sp_virus:
795: sp_vertebrate:
796: sp_unclassified:
797: sp_rvirus:
798: sp_bacteria:
799: sp_fungi:
800: sp_invertebrate:
801: sp_mammal:
802: sp_mhc:
803: sp_organelle:
804: sp_phage:
805: sp_plant:
806: sp_rabbit:
807: sp_virus:
808: sp_vertebrate:
809: sp_unclassified:
810: sp_rvirus:
811: sp_bacteria:
812: sp_fungi:
813: sp_invertebrate:
814: sp_mammal:
815: sp_mhc:
816: sp_organelle:
817: sp_phage:
818: sp_plant:
819: sp_rabbit:
820: sp_virus:
821: sp_vertebrate:
822: sp_unclassified:
823: sp_rvirus:
824: sp_bacteria:
825: sp_fungi:
826: sp_invertebrate:
827: sp_mammal:
828: sp_mhc:
829: sp_organelle:
830: sp_phage:
831: sp_plant:
832: sp_rabbit:
833: sp_virus:
834: sp_vertebrate:
835: sp_unclassified:
836: sp_rvirus:
837: sp_bacteria:
838: sp_fungi:
839: sp_invertebrate:
840: sp_mammal:
841: sp_mhc:
842: sp_organelle:
843: sp_phage:
844: sp_plant:
845: sp_rabbit:
846: sp_virus:
847: sp_vertebrate:
848: sp_unclassified:
849: sp_rvirus:
850: sp_bacteria:
851: sp_fungi:
852: sp_invertebrate:
853: sp_mammal:
854: sp_mhc:
855: sp_organelle:
856: sp_phage:
857: sp_plant:
858: sp_rabbit:
859: sp_virus:
860: sp_vertebrate:
861: sp_unclassified:
862: sp_rvirus:
863: sp_bacteria:
864: sp_fungi:
865: sp_invertebrate:
866: sp_mammal:
867: sp_mhc:
868: sp_organelle:
869: sp_phage:
870: sp_plant:
871: sp_rabbit:
872: sp_virus:
873: sp_vertebrate:
874: sp_unclassified:
875: sp_rvirus:
876: sp_bacteria:
877: sp_fungi:
878: sp_invertebrate:
879: sp_mammal:
880: sp_mhc:
881: sp_organelle:
882: sp_phage:
883: sp_plant:
884: sp_rabbit:
885: sp_virus:
886: sp_vertebrate:
887: sp_unclassified:
888: sp_rvirus:
889: sp_bacteria:
890: sp_fungi:
891: sp_invertebrate:
892: sp_mammal:
893: sp_mhc:
894: sp_organelle:
895: sp_phage:
896: sp_plant:
897: sp_rabbit:
898: sp_virus:
899: sp_vertebrate:
900: sp_unclassified:
901: sp_rvirus:
902: sp_bacteria:
903: sp_fungi:
904: sp_invertebrate:
905: sp_mammal:
906: sp_mhc:
907: sp_organelle:
908: sp_phage:
909: sp_plant:
910: sp_rabbit:
911: sp_virus:
912: sp_vertebrate:
913: sp_unclassified:
914: sp_rvirus:
915: sp_bacteria:
916: sp_fungi:
917: sp_invertebrate:
918: sp_mammal:
919: sp_mhc:
920: sp_organelle:
921: sp_phage:
922: sp_plant:
923: sp_rabbit:
924: sp_virus:
925: sp_vertebrate:
926: sp_unclassified:
927: sp_rvirus:
928: sp_bacteria:
929: sp_fungi:
930: sp_invertebrate:
931: sp_mammal:
932: sp_mhc:
933: sp_organelle:
934: sp_phage:
935: sp_plant:
936: sp_rabbit:
937: sp_virus:
938: sp_vertebrate:
939: sp_unclassified:
940: sp_rvirus:
941: sp_bacteria:
942: sp_fungi:
943: sp_invertebrate:
944: sp_mammal:
945: sp_mhc:
946: sp_organelle:
947: sp_phage:
948: sp_plant:
949: sp_rabbit:
950: sp_virus:
951: sp_vertebrate:
952: sp_unclassified:
953: sp_rvirus:
954: sp_bacteria:
955: sp_fungi:
956: sp_invertebrate:
957: sp_mammal:
958: sp_mhc:
959: sp_organelle:
960: sp_phage:
961: sp_plant:
962: sp_rabbit:
963: sp_virus:
964: sp_vertebrate:
965: sp_unclassified:
966: sp_rvirus:
967: sp_bacteria:
968: sp_fungi:
969: sp_invertebrate:
970: sp_mammal:
971: sp_mhc:
972: sp_organelle:
973: sp_phage:
974: sp_plant:
975: sp_rabbit:
976: sp_virus:
977: sp_vertebrate:
978: sp_unclassified:
979: sp_rvirus:
980: sp_bacteria:
981: sp_fungi:
982: sp_invertebrate:
983: sp_mammal:
984: sp_mhc:
985: sp_organelle:
986: sp_phage:
987: sp_plant:
988: sp_rabbit:
989: sp_virus:
990: sp_vertebrate:
991: sp_unclassified:
992: sp_rvirus:
993: sp_bacteria:
994: sp_fungi:
995: sp_invertebrate:
996: sp_mammal:
997: sp_mhc:
998: sp_organelle:
999: sp_phage:
1000: sp_plant:
1001: sp_rabbit:
1002: sp_virus:
1003: sp_vertebrate:
1004: sp_unclassified:
1005: sp_rvirus:
1006: sp_bacteria:
1007: sp_fungi:
1008: sp_invertebrate:
1009: sp_mammal:
1010: sp_mhc:
1011: sp_organelle:
1012: sp_phage:
1013: sp_plant:
1014: sp_rabbit:
1015: sp_virus:
1016: sp_vertebrate:
1017: sp_unclassified:
1018: sp_rvirus:
1019: sp_bacteria:
1020: sp_fungi:
1021: sp_invertebrate:
1022: sp_mammal:
1023: sp_mhc:
1024: sp_organelle:
1025: sp_phage:
1026: sp_plant:
1027: sp_rabbit

DR	PRODom: PDD01838; PROSITE: PS00946; CATHELICIDINS 1; 1.	Streptomyces coelicolor; Actinobacteria; Streptomyces.
DR	PROSITE: PS00947; CATHELICIDINS 2; 1.	
KW	Signal; Antibiotic.	
FT	SIGNAL 1 29	POTENTIAL.
FT	PROPEP 30 130	POTENTIAL.
FT	PROPEP CHAIN 131 224	BACTINECIN 11.
FT	MOD_RES 30 30	PYRROLIDONE CARBOXYLIC ACID (BY SIMILARITY).
FT	DISULFID 85 96	BY SIMILARITY.
FT	DISULFID 107 124	BY SIMILARITY.
FT	SEQUENCE 224 AA; 25669 MW;	6EARAB1256AC76FC CRC64;
Query Match	Score 58; DB 6; Length 224; Best Local Similarity 78.6%; Ptd. No. 1.6; Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;	
Qy	1 RRRRPPPYLPRRPP 14	
Db	132 RLRRPRERLPRRPP 145	
RESULT 6		
Q94J98	PRELIMINARY; ID: Q94J98; AC: Q94J98; DT: 01-DEC-2001 (TREMBLrel. 19, Created) DT: 01-DEC-2001 (TREMBLrel. 19, Last sequence update) DT: 01-JUN-2002 (TREMBLrel. 21, Last annotation update) DE: P0047508.14 Protein (Q0J159_D09.5 protein). DE: P0047508.14 OR Q0J159_D09.5.	
OS	Oryza sativa (Rice), and	
OC	Bukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poaceae; Phrithotidae; Oryzeae; Oryza.	
OC	Q94J98; OX: NCBI_TaxID:4530; 39947; RN: [1] SEQUENCE FROM N.A.	
RP	SEQUENCE FROM N.A.	
RC	STRAIN-CV: NIPPONBARE; Sasaki T., Matsumoto T., Yamamoto K.; "Oryza sativa (japonica cultivar-group) genomic DNA, chromosome 1, PAC clone P0047508.14" Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.	
RL	Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.	
RN	SEQUENCE FROM N.A.	
RP	STRAIN-CV: NIPPONBARE; Sasaki T., Matsumoto T., Yamamoto K.; "Oryza sativa (japonica cultivar-group) genomic DNA, chromosome 1, BAC clone Q0J159_D09"; Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.	
DR	EMBL: AP003053; BAB55630.1; -.	
DR	EMBL: AP003192; BAB89188.1; -.	
SQ	SEQUENCE 183 AA; 20155 MW;	FLCE823ND89CEB36 CRC64;
Query Match	Score 57.5; DB 10; Length 183; Best Local Similarity 73.3%; Ptd. No. 1.6; Matches 11; Conservative 1; Mismatches 2; Indels 1; Gaps 1;	
Qy	1 RRRRPPPYLPRRPP 15	
Db	129 RSRPR-PYAPRQQP 142	
RESULT 7		
Q9RK54	PRELIMINARY; ID: Q9RK54; AC: Q9RK54; DT: 01-MAY-2000 (TREMBLrel. 13, Created) DT: 01-MAY-2000 (TREMBLrel. 13, Last sequence update) DT: 01-JUN-2002 (TREMBLrel. 21, Last annotation update) HYPOTHETICAL protein SCO0323.	
OS	Bacteria; Firmicutes; Actinobacteria; Streptomyces.	
OC	Actinomycetaceae; Streptomyceae.	
NCBI_TaxID:1902;	[1] SEQUENCE FROM N.A.	
OX	RN: RP STRAIN=A3 (2) / M145; RA: Bentley S.D., Chater K.F., Cerdeno-Taronga A.-M., Challis G.L., Thomson N.R., James K.D., Harris D.E., Quail M.A., Kieser H., Harper D., Bateman A., Brown S., Chandra G., Chen C.W., Collins M., Cronin A., Fraser A., Goble A., Hidalgo J., Hornsby T., Howarth S., Huang C.H., Kieser T., Larke L., Murphy L., Oliver K., O'Neil S., Rabbinkowitzsch B., Rajandream M.A., Rutherford K., Rutter S., Seeger K., Saunders D., Sharp S., Squares R., Squares S., Taylor K., Warren T., Wictorrek A., Woodward J., Barrell B.G., Parkhill J., Hopwood D.A.;	
	RT: "Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2)." RL: Nature 417:141-147(2002). DR: EMBL: AU117669; CAB56128.1; -.	
KW	KW: HYPOTHETICAL protein.	
SQ	SEQUENCE 200 AA; 22076 MW;	0DCBEC5585803B5 CRC64;
Query Match	Score 57; DB 16; Length 200; Best Local Similarity 76.9%; Pred. No. 2; Matches 10; Conservative 0; Mismatches 3; Indels 0; Gaps 0;	
Qy	1 RRRRPPPYLPRRPP 13	
Db	118 RRHDEPPALPRR 130	
RESULT 8		
Q9XCG4	PRELIMINARY; ID: Q9XCG4; AC: Q9XCG4; DT: 01-NOV-1999 (TREMBLrel. 12, Created) DT: 01-DEC-2001 (TREMBLrel. 19, Last annotation update)	
OS	Mycobacterium avium.	
OC	Bacteria; Firmicutes; Actinobacteria; Streptomyctaceae; Mycobacterium.	
NCBI_TaxID:1764;	RN: [1] SEQUENCE FROM N.A.	
RP	SEQUENCE FROM N.A.	
RC	Eckstein T.M., Lambert M.L., Brennan P.J., Belisle J.T., Inamine J.M., RA: "Identification of a gene cluster involved in glycopeptidolipid biosynthesis and of a gene cluster encoding daunorubicin resistance in two strains of Mycobacterium avium serovar 2." Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.	
DR	EMBL: AF143772; AA044199.1; -.	
KW	KW: HYPOTHETICAL protein.	
SQ	SEQUENCE 361 AA; 40208 MW;	AD01DBB825C1C9EA CRC64;
Query Match	Score 57; DB 2; Length 361; Best Local Similarity 71.4%; Pred. No. 3.4; Matches 10; Conservative 0; Mismatches 4; Indels 0; Gaps 0;	
Qy	1 RRRRPPPYLPRRPP 14	
Db	32 RRRRPPAPRHPPPP 45	
RESULT 9		
Q0B306	PRELIMINARY; ID: Q0B306; AC: Q0B306; DT: 01-JUL-1997 (TREMBLrel. 04, Created) DT: 01-JUL-1997 (TREMBLrel. 04, Last sequence update) DT: 01-DEC-2001 (TREMBLrel. 19, Last annotation update)	
OS	HYPOTHETICAL protein SCO0323.	
OC	DE: 22.7 kDa protein.	

OS	No cardioidea simplex (Arthrobacter simplex).	Matches	9;	Conservative	1;	Mismatches	2;	Indels	0;	Gaps	0;
OC	Bacteria; Firmicutes; Actinobacteria; Actinomycetales; Propionibacterineae; Nocardioidaceae; Pimelobacter.	Qy	4	PRPPYLPRPPP 15							
OX	NCBI_TaxID=2045;	Db	136	PSPPPLRQQPP 147							
RN											
SEQUENCE FROM N.A.											
STRAIN=IFO12069;											
RC											
RX	PubMed=7596291;										
RA	Medline=95319331;										
RT	Molecular cloning, expression in Streptomyces lividans, and analysis of a gene cluster from Arthrobacter bomyx encoding 3-ketosteroid-DEhydrogenase, 3-ketosteroid- β -DEhydrogenase, and a hypothetical regulatory protein.";										
RT	Submitted (MAR-1997) to the EMBL/Genbank/DBJ databases.										
RT	-1- SIMILARITY: BELONGS TO THE TETR/ACR FAMILY OF TRANSCRIPTIONAL REGULATORS.										
CC											
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE										
CC	EMBL; Z93338; CAB07542.1; -.										
CC	InterPro: IPR001647; HTH_Tetr.										
CC	PFM; PF0440; CetR; 1.										
CC	PRINTS; PR0455; HTHTETR.										
CC	PROSITE; PS01081; HTH_TETR_FAMILY; 1-DNA-Binding; Hypothetical Protein; transcription regulation.										
CC	SEQUENCE					</td					

Query Match Similarity 60.6%; Score 54.5; DB 10; Length 301;
 Best Local Similarity 71.4%; Pred. No. 6; Neipel F., Albrecht J.-C., Ensser A., Huang Y.-Q., Li J.-J.,
 Matches 10; Conservative 1; Mismatches 2; Indels 1; Gaps 1;
 RN [2] SEQUENCE FROM N.A.
 RP Neipel F., Albrecht J.-C., Ensser A., Huang Y.-Q., Li J.-J.,
 RA Friedmann-Kien A.E., Fleckenstein B.;
 RA "The genome of human herpesvirus 8 cloned from Kaposi's sarcoma.";
 RI "The genome of human herpesvirus 8 submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.
 RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL: U93872; ARB62660.1; -.
 SQ SEQUENCE 2635 AA; 289/17 MW; 91DDA0D6FF78660A CRC64;

RESULT 13
 P88955 PRELIMINARY; PRT; 2635 AA.
 ID P88955
 AC P88955;
 DT 01-MAY-1997 (TREMBLrel. 03, Created)
 DT 01-MAY-1997 (TREMBLrel. 03, Last sequence update)
 DT 01-DEC-2001 (TREMBLrel. 19, Last annotation update)
 DB ORF 64.
 OS Kaposi's sarcoma-associated herpesvirus (KSHV) (Human herpesvirus 8).
 OC Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
 OC Gammaherpesvirinae; Rhadinoviridae;
 OX NCBI_TaxID=37296;
 RN [1] SEQUENCE FROM N.A.
 RP MEDLINE=97094384; PubMed=8939871;
 RX RA Moore P.S., Boshoff C., Weiss R.A., Chang Y.;
 RA "Molecular mimicry of human cytokine and cytokine response pathway
 genes by KSHV";
 RT Science 274:1739-1744 (1996).
 RL [12] SEQUENCE FROM N.A.
 RX MEDLINE=97121480; PubMed=8962146;
 RA Russo J.J., Bohenzky R.A., Chien M.-C., Chen J., Yan M., Maddalena D.,
 RA Parry J.P., Peruzzi D., Edelman I.S., Chang Y., Moore P.S.;
 RT "Nucleotide sequence of the Kaposi's sarcoma-associated herpesvirus
 (HHV8)." ;
 RT Proc. Natl. Acad. Sci. U.S.A. 93:14862-14867(1996).
 RL [13] SEQUENCE FROM N.A.
 RN [1] SEQUENCE FROM N.A.
 RP Russo J.J., Bohenzky R.A., Chien M.-C., Chen J., Yan M., Maddalena D.,
 RA Parry J.P., Peruzzi D., Edelman I.S., Chang Y., Moore P.S.;
 RA Submitted (MAY-1997) to the EMBL/GenBank/DBJ databases.
 RT EMBL: U75698; AAC57149.1; -.
 RL DR 00070132EA8119AF CRC64;
 SQ SEQUENCE 2635 AA; 289/687 MW; 00070132EA8119AF CRC64;

Query Match Similarity 60.6%; Score 54.5; DB 12; Length 2635;
 Best Local Similarity 68.4%; Pred. No. 44; Neipel F., Albrecht J.-C., Ensser A., Huang Y.-Q., Li J.-J.,
 Matches 13; Conservative 0; Mismatches 1; Indels 5; Gaps 2;
 RN [2] SEQUENCE FROM N.A.
 RP MEDLINE=97096220; PubMed=9151804;
 RX Neipel F., Albrecht J.C., Fleckenstein B.;
 RA "Cell-homologous genes in the Kaposi's sarcoma-associated rhabdovirus
 human herpesvirus 8: determinants of its pathogenicity?";
 RI "Cell-homologous genes in the Kaposi's sarcoma-associated rhabdovirus
 human herpesvirus 8: determinants of its pathogenicity?";
 RL J. Virol. 71:4187-4192(1997).
 RL

RESULT 14
 O40942 PRELIMINARY; PRT; 2635 AA.
 ID O40942
 AC O40942;
 DT 01-JAN-1998 (TREMBLrel. 05, Created)
 DT 01-JAN-1998 (TREMBLrel. 05, Last sequence update)
 DT 01-DEC-2001 (TREMBLrel. 19, Last annotation update)
 DB ORF 64.
 OS Kaposi's sarcoma-associated herpesvirus (KSHV) (Human herpesvirus 8).
 OC Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
 OC Gammaherpesvirinae; Rhadinovirus.
 OX NCBI_TaxID=37296;
 RN [1] SEQUENCE FROM N.A.
 RP MEDLINE=97096220; PubMed=9151804;
 RX Neipel F., Albrecht J.C., Fleckenstein B.;
 RA "Cell-homologous genes in the Kaposi's sarcoma-associated rhabdovirus
 human herpesvirus 8: determinants of its pathogenicity?";
 RI "Cell-homologous genes in the Kaposi's sarcoma-associated rhabdovirus
 human herpesvirus 8: determinants of its pathogenicity?";
 RL J. Virol. 71:4187-4192(1997).
 RL

THIS PAGE BLANK (USPTO)